

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/52, 5/10, 9/64, C12Q 1/37, 1/68, A61K 31/70, 38/43, A01K 67/027, G01N 33/50	A2	(11) International Publication Number: WO 00/04157 (43) International Publication Date: 27 January 2000 (27.01.00)
(21) International Application Number: PCT/GB99/02241 (22) International Filing Date: 14 July 1999 (14.07.99) (30) Priority Data: 9815284.6 14 July 1998 (14.07.98) GB (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): PANGALOS, Menlas [GB/GB]; 136 Beaufort Park, London NW11 6DA (GB). NEEFS, Jean-Marc, Edmond, Fernand, Marie [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). PEETERS, Danielle, Celine, Georgette [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). (74) Agent: BOULT WADE TENNANT; 27 Fumival Street, London EC4A 1PQ (GB).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: CLONING AND CHARACTERISATION OF NOVEL MAMMALIAN PEPTIDASES (57) Abstract There is disclosed a cDNA molecule encoding human NAALAD-ases designated herein as I, II and IV and having the amino acid sequences illustrated in Figures 1, 3, 4 and 5. The NAALAD-ases themselves also form part of the invention. Further provided are expression vectors incorporating the cDNA molecules suitable for transforming a cell, tissue or organism.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**CLONING AND CHARACTERISATION OF
NOVEL MAMMALIAN PEPTIDASES**

The present invention is concerned with novel
5 mammalian peptidases and, in particular, with
peptidases designated NAALAD-ase (N-acetylated alpha-
linked acidic dipeptidases), cDNA sequences encoding
for said peptidases and methods of identifying
10 compounds which inhibit or enhance the activity or
expression of such peptidases in addition to the
compounds so identified.

NAALAD-ase I has previously been identified as a
type II membrane glycoprotein with carboxypeptidase
activity and sequence similarity to the transferrin
15 receptor and which may be important in the progression
of prostate cancer, being highly expressed in prostate
tumours. In the CNS it has been postulated to have a
role in modulating neuronal glutamergic activity. The
nucleotide and amino acid sequences for NAALAD-ase I
20 have previously been identified (US 5,538,686).

The present inventors have now surprisingly
identified and cloned cDNA molecules which represent
an expansion of this family of proteins and which
enzymes have never previously been identified or
25 characterised.

Therefore, according to a first aspect of the
present invention, there is provided a cDNA molecule
encoding a peptidase designated human NAALAD-ase L
having the amino acid sequence illustrated in Figure 1
30 or a functional equivalent or derivative or
bioprecursor thereof. Preferably, the cDNA molecule
comprises the sequence of nucleotides illustrated in
Figure 1. Also provided by the present invention are
splice variants of the human NAALAD-ase L protein
35 illustrated in Figure 3 and preferably which splice
variants are encoded by the nucleotide deletions or

insertions indicated in Figure 3.

According to a further aspect of the present invention there is provided a cDNA molecule encoding a peptidase designated NAALAD-ase II or IV having the amino acid sequences as illustrated in Figures 4 and 5 respectively. Preferably, the cDNA comprises the sequences of nucleotides illustrated in Figures 4 and 5 respectively. Also encompassed within the present invention are nucleic acid molecules capable of hybridising to the cDNA molecules according to the invention.

Also provided by the present invention are the NAALAD-ase proteins encoded by the DNA sequences according to the invention. Therefore, according to a further aspect of the invention there is provided a human NAALAD-ase L protein having an amino acid sequence encoded by the nucleotide sequence illustrated in Figure 1 or the sequence of Figure 1 including the insertions or deletions illustrated in Figure 3. Preferably, the NAALAD-ase L protein comprises a human NAALAD-ase L protein. Also provided by the present invention is a NAALAD-ase II and IV protein having amino acid sequences encoded by the nucleotide sequences illustrated in Figure 4 and 5 respectively or a functional equivalent, derivative or bioprecursor thereof and which protein is preferably of human origin. Preferably, the NAALAD-ase II and IV proteins comprise the amino acid sequences illustrated in Figures 4 and 5 respectively.

There is also provided by the invention an antisense molecule capable of hybridising to any of the nucleic acid sequences according to the invention, under high stringency conditions, which would be well known to those skilled in the art.

Stringency of hybridisation as used herein refers to conditions under which polynucleic acids are stable. The stability of hybrids is reflected in the

- 3 -

melting temperature (T_m) of the hybrids. T_m can be approximated by the formula:

$$81.5^{\circ}\text{C} - 16.6 (\log_{10}[\text{Na}^+] + 0.41 (\% \text{G\&C}) - 600/1$$

5

wherein l is the length of the hybrids in nucleotides. T_m decreases approximately by $1-1.5^{\circ}\text{C}$ with every 1% decrease in sequence homology.

10 The cDNA molecules according to the invention may advantageously be included in an expression vector which may itself be used to transform, transfect or infect a host cell, which cell may be bacterial or eukaryotic in origin. Thus, advantageously, a range of cells, tissues or organisms may be transfected
15 following incorporation of the appropriate cDNA into the expression vector. The vector may include an appropriate promoter, such as a cytomegalovirus promoter and optionally a sequence encoding a reporter molecule such as, for example, green fluorescent
20 protein.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector
25 may include a promoter such as the lac promoter and for transcription initiations the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector may include a heterologous or homologous promoter for RNA polymerase
30 II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art.

35 Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that upon

introduction into an appropriate host cell results in expression of the DNA or RNA fragments. Appropriate expression vectors are well known to those skilled in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

The antisense molecule capable of hybridising to the nucleic acid according to the invention may be used as a probe or as a medicament or in a pharmaceutical composition.

Nucleic acid molecules according to the invention may be inserted into the vectors described in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense nucleic acids may be produced by synthetic means.

A further aspect of the invention comprises the host cell transformed, transfected or infected with the expression vector according to the invention, which cell preferably comprises a eukaryotic cell and more preferably a mammalian cell.

Incorporation of cloned DNA into a suitable expression vector for subsequent transformation of said cell and subsequent selection of the transformed cells is well known to those skilled in the art as provided in Sambrook et al (1989) Molecular Cloning, A Laboratory manual, Cold Spring Harbour Laboratory Press.

The present invention also comprises a transgenic cell, tissue or organism comprising a transgene, capable of expressing a NAALAD-ase protein according to the invention.

The term "transgene capable" of expression the protein according to the invention, as used herein should be taken to mean a suitable nucleic acid sequence which leads to the expression of said protein

- 5 -

according to the invention or a protein having the same function or activity. The transgene may include, for example, genomic nucleic acid isolated from a human source or synthetic nucleic acid, inducing cDNA.

5 The term "transgenic organism, tissue or cell" as used herein means any suitable organism and/or part of an organism, tissue or cell, that contains exogenous nucleic acid either stably integrated in the genome or in an extrachomosomal state. The transgenic cell is

10 preferably a COS cell. Preferably, the transgene comprises an expression vector according to the invention.

The term "functional fragment" as used herein should be taken to mean a fragment of the gene encoding the NAALAD-ase protein according to the

15 invention. For example, the gene may comprise deletions or mutations but may still encode a functional NAALAD-ase protein.

In accordance with the present invention, a

20 defined nucleic acid sequence includes not only the identical nucleic acid but also minor base variations from the natural nucleic acid sequence, including in particular, substitutions in bases which result in a synonymous codon (a different codon specifying the

25 same amino acid) due to the degenerate code in conservative amino acid substitution. The term "nucleic acid or cDNA sequence" also includes the complementary sequence to any single stranded sequence given which includes the definition given above

30 regarding base variations.

Furthermore, a defined protein, polypeptide or amino acid sequence according to the invention includes not only the identical amino acid sequence but also minor amino acid variations from the natural

35 amino acid sequence including conservative amino acid replacements (a replacement by an amino acid that is related in its side chains). Also included are amino

- 6 -

acid sequences which vary from the natural amino acid but result in a polypeptide which is immunologically identical or similar to the polypeptide encoded by the naturally occurring sequence.

5 A further aspect of the invention provides a nucleic acid sequence of at least 15 nucleotides of a nucleic acid according to the invention and preferably from 15 to 50 nucleotides.

10 These sequences may, advantageously be used as probes or primers to initiate replication or the like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting for the
15 presence of a nucleic acid according to the invention. These tests generally comprise contacting the probe with a sample under hybridising conditions and detecting for the presence of any duplex formation between the probe and any nucleic acid in the sample.

20 Nucleic acid sequences according to the invention may also be produced using recombinant or synthetic means such as described in Sambrook et al (Molecular Cloning: A Laboratory Manual, 1989). Advantageously, human allelic variants or polymorphisms of the DNA
25 according to the invention may be identified by, for example, probing DNA libraries from a range of individuals for example from different populations. Furthermore, nucleic acids and probes according to the invention may be used to sequence genomic DNA from
30 patients using techniques well known in the art, such as the Sanger Dideoxy chain termination method, which may advantageously ascertain any predisposition of a patient to certain proliferative disorders.

35 The nucleic acids or oligonucleotides according to the invention may carry a revealing label. Suitable labels include radioisotopes such as ³²P or ³⁵S, enzyme labels or other protein labels such as biotin or

fluorescent markers. Such labels may be added to the nucleic acids or oligonucleotides of the invention and may be detected using known techniques *per se*.

Advantageously, human allelic variants or
5 polymorphisms of the DNA molecule according to the invention may be identified by, for example, probing cDNA or genomic libraries from a range of individuals for example from different populations. Furthermore, nucleic acids and probes according to the invention
10 may be used to sequence genomic DNA from patients using techniques well known in the art, such as the Sanger Dideoxy chain termination method, which may advantageously ascertain any predisposition of a patient to certain disorders associated with a
15 NAALAD-ase according to the invention.

A nucleic acid sequence or protein identified according to the present invention may advantageously be used as a medicament, or in the preparation of a medicament for treating cancer or neurodegenerative
20 disorders such as Alzheimer's disease or ALS, and other diseases or disorders mediated by peptidases according to the present invention. Advantageously, the cDNA and protein according to the invention in addition to nucleic acids hybridisable to the cDNA may
25 also be included in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor. Thus, the composition may comprise antisense nucleic acids for use in, for example, gene therapy.

30 The present invention is further directed to inhibiting a NAALAD-ase according to the invention *in vivo* by the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or
35 RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the part of the DNA sequence coding for the mature protein of

- 8 -

the present invention is used to design an antisense RNA oligonucleotide of from 10 to 50 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple-helix - see Lee et al. Nucl. Acids. Res., 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991), thereby preventing transcription and the production of the peptidase. The antisense RNA oligonucleotide hybridises to the mRNA *in vivo* and blocks translation of an mRNA molecule into the NAALAD-ase.

Further provided by the present invention is a method of determining whether a compound is an inhibitor or an enhancer of NAALAD-ase activity, which method comprises contacting said compound in the present of [³H]N-acetyl-L-aspartyl-L-glutamate (NAAG), and monitoring for the extent of hydrolysis of said NAAG.

NAALAD-ase peptides have previously been reported to have a role in prostate and other potential cancers in which case compounds identified as either inhibitors or enhancers of NAALAD-ase activity may advantageously be used as medicaments, or in the preparation of medicaments for treating cancers or neurodegenerative diseases such as Alzheimer's disease or ALS. These compounds may also be included in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

A further aspect of the present invention comprises a method of identifying a compound which is an inhibitor or an enhancer of expression of a NAALAD-ase protein according to the invention which method comprises contacting a host cell, tissue or organism expressing said protein with said compound and monitoring the expression of said protein compared to

- 9 -

a control which comprises a cell expressing said peptidase according to the invention but which has not been contacted with said compound.

Preferably, said NAALAD-ase expressing cell
5 comprises a host cell according to the invention or a transgenic cell, tissue or organism as described above. Preferably, said monitoring step comprises monitoring for the expression of said reporter molecule.

10 Compounds identified according to the above identified method may also be used as a medicament or in the preparation of a medicament for treating neurodegenerative disorders such as Alzheimer's disease, schizophrenia or ALS. Such compounds may
15 also be included in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor to the present invention may also be prepared.

The NAALAD-ase antisense molecules or indeed the
20 compounds identified as agonists or antagonists of the NAALAD-ase according to the invention may be used in the form of a pharmaceutical composition, which may be prepared according to procedures well known in the art. Preferred compositions include a
25 pharmaceutically acceptable vehicle or diluent or excipient, such as for example, a physiological saline solution. Other pharmaceutically acceptable carriers including other non-toxic salts, sterile water or the like may also be used. A suitable buffer may also be
30 present allowing the compositions to be lyophilized and stored in sterile conditions prior to reconstitution by the addition of sterile water for subsequent administration. Incorporation of
35 NAALAD-ase into a solid or semi-solid biologically compatible matrix may be carried out which can be implanted into tissues requiring treatment.

Antibodies to the NAALAD-ase peptidases according

- 10 -

to the present invention may, advantageously be prepared according to those techniques known in the art. Polyclonal antibodies against these peptides may be produced by immunizing animals using the selected peptides. Monoclonal antibodies are prepared using hybridoma technology by fusing antibody producing B cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody. Alternatively, monoclonal antibodies may be produced in *in vitro* techniques known to persons of ordinary skill in the art.

The antibodies prepared may be used in a method for detecting for the presence of said NAALAD-ase peptidases according to the invention by reacting said antibodies with a sample to be tested and identifying any protein bound thereto. A kit for such a method may also be provided and which comprises an antibody according to the aspect of the invention described above and means for reacting said antibody with said sample.

The carrier can also contain other pharmaceutically acceptable excipients for modifying other conditions such as pH, osmolarity, viscosity, sterility, lipophilicity, solubility or the like. Pharmaceutically acceptable excipients which permit sustained or delayed release following administration may also be included.

The NAALAD-ase protein or the nucleic acid molecules or compounds according to the invention may be administered orally. In this embodiment they may be encapsulated and combined with suitable carriers in solid dosage forms which would be well known to those skilled in the art.

As would be well known to those of skill in the art, the specific dosage regime may be calculated according to the body surface area of the patient or the volume of body space to be occupied, dependent

- 11 -

upon the particular route of administration to be used. The amount of the composition actually administered will, however, be determined by a medical practitioner, based on the circumstances pertaining to the disorder to be treated, such as the severity of the symptoms, the composition to be administered, the age, weight, and response of the individual patient and the chosen route of administration.

A functionally active dose of such compounds according to the present invention comprises 300 ng/kg to 300 μ g/kg in a rat. As aforementioned a skilled practitioner would arrive at an appropriate dosage for human subjects based on the relevant factors discussed.

The present invention may be more clearly understood by the following examples, which are purely exemplary, with reference to the accompanying drawings wherein:

Figure 1: is an illustration of the nucleotide and amino acid sequences of human NAALAD-ase L. The nucleotide and predicted single letter code amino acid sequence are shown. the putative membrane spanning domain, deduced from hydrophilicity plots, is marked by a line. Potential N-glycosylation sites are shaded.

Figure 2: is an alignment of the predicted protein sequences for human and rat NAALAD-ase L. The amino acid sequences were aligned using the ClustalW alignment program (EMBL, Heidelberg Germany). Amino acid residues identical in both proteins are highlighted in black. Amino acid residues are numbered in the right hand margin.

Figure 3: is an illustration of alternative splicing of NAALAD-ase L. Amino acid sequence for NAALAD-ase L

- 12 -

is shown. Sites at which putative DNA sequences are spliced out are marked by an arrow with the resulting (in-frame) amino acid deletions highlighted in bold italicised letters. Sites of putative intronic DNA insertion are marked by triangles, with the intronic DNA sequence shown above. Resulting changes to the amino acid sequence are highlighted in bold italicised letters. Numbering of amino acid residues is to the right.

10

Figure 4: is a nucleotide and amino acid sequence of human NAALAD-ase II. The nucleotide and predicted one letter code amino acid sequence are shown. The putative membrane spanning domain, deduced from hydrophilicity plots, is marked by a line. Potential N-glycosylation sites are shaded.

15

Figure 5: is a nucleotide sequence and amino acid sequence of human NAALAD-ase IV. The nucleotide and predicted one letter code amino acid sequence are shown. The putative membrane spanning domain, deduced from hydrophilicity plots, is marked by a line. Potential N-glycosylation sites are shaded.

20

Figure 6: is an alignment of the predicted protein sequences for human NAALAD-ases I, L, II & IV. The amino acid sequences were aligned using the ClustalW alignment program. Amino acid residues identical to all four proteins are shaded in black. Amino acid residues identical to three of the four proteins are shaded in grey. Amino acid residues are numbered to the right. A putative Zn^{2+} peptidase domain is highlighted between arrows and was identified by comparison to yeast and bacterial aminopeptidases. Putative residues involved in the catalytic site of the α/β hydrolase fold family of proteins are marked by three arrows (nucleophile-acid-base).

25

30

35

- 13 -

Figure 7: is a phylogram of NAALAD-ase I, L, II and IV. The human and rat sequences were used and the alignments performed with the CLUSTALW program. The tree was constructed using the GCG 'Distances' program with standard parameters and the 'Growtree' program with the UPGMA method.

Figure 8: is an alignment of the NAALAD-ase peptidase domains with related peptidases. Amino acid sequences were aligned using the standard settings of CLUSTALW alignment program. Similar amino acid residues conserved in proteins are shaded in black. Similar amino acid residues conserved in 80% of the proteins are shaded in dark grey. Similar amino acid residues conserved in 60-79% of the proteins are shaded in light grey. Amino acid residues are numbered to the right. Putative residues involved in zinc binding are marked by asterisks. The base residue thought to be important in catalysis is marked by an arrow.

Sequence names other than NAALAD-ases correspond to sequence accession numbers in Swiss-Prot and SPTREMBL; Ape 3 yeast, *Saccharomyces cerevisiae* aminopeptidase Y; P96152, *Vibrio cholerae* aminopeptidase; .Ampx vibpr, *Aeromonas proteolytica* aminopeptidase, Application strgr, *Streptomyces griseus* aminopeptidase. Putative residues involved in zinc binding are marked by asterisks. General base residue thought to be important in catalysis is marked by an arrow.

Figure 9: is an illustration of time course of NAALAD-ase activity. Activity of membrane preparations from COS cells transiently transfected with either NAALAD-ase I (A) or NAALAD-ase L (B). Hydrolysis of 500 nM 3[H]-NAAG in 1mM ZnCl₂, 50 mM Tris.HCL (pH 7.4) was assayed for 0, 15, 30 and 60 min at 37°C in the presence (open circles) or absence (closed circles) of 30 µM quisqualate. Reactions were terminated with 250

- 14 -

mM ice cold sodium phosphate and released 3[H]-glutamate measured. (C) Inhibition of NAALAD-ase I (open circles) and NAALAD-ase II (closed circles) activity by increasing concentrations of quisqualic acid expressed as % of control (activity in the absence of any inhibitor).

Figure 10: is an illustration of NAALAD-ase activity determinations using SPA beads. (A) 10 µg of protein from LNCaP cell membrane preparations was used per reaction to develop a high throughput assay NAALAD-ase assay. Hydrolysis of 40 nM 3[H]-NAAG in 1mM ZnCl₂, 50 mM Tris-HCL (pH 7.4) was measured at 25°C for different incubation times in a 100 µl reaction volume. Reactions were terminated by the addition of 100 µl glycine buffer (pH 3.0) and naked YS-SPA beads. (C) Inhibition of NAALAD-ase I (open circles) or LNCaP membrane NAALAD-ase (closed circles) activity by increasing concentrations of quisqualic acid expressed as a % of control (activity in the absence of any inhibitor).

Figure 11: is an illustration of chromosomal localisation of human NAALAD-ases. Diagrams of FISH mapping results for NAALAD-ase I (A), L (C) II (E) and IV (G). In each diagram dots represent the double FISH signals detected on identified chromosomes. Examples of FISH mapping of NAALAD-ase I (B), L (D), II (F) and IV (:H). Left panels show the FISH signals on the identified chromosome marked by a white arrow, right panels show the same mitotic Figure stained with DAI to identify the chromosome.

Figure 12: is an illustration of northern blot analysis of NAALAD-ase II and IV expression. Human multiple tissue Northern blots (Klondike) containing 2 µg per lane of poly (A)+ RNA were hybridised with a

- 15 -

³²p-labelled NAALAD-ase II (A) or IV (B) probes at 68°C and washed at high stringency (final washes at 50°C with 1/10 dilution of SSC/0.1 % SDS).

5 Autoradiographic exposure was done after 3 to 7 days at -70°C with two intensifying screens. Molecular mass markers are indicated in bp on the left hand side of each autoradiogram.

10 Figure 13: is an illustration of RT-PCR analysis of NAALAD-ase expression in different tissues. PCR amplifications with primers specific for human NAALAD-ase I (A), L (B), II (C) and IV (D) or GAPDH (E) were performed on normalised human MTC cDNAsTM for 25, 30 and 35 cycles. Images from ethidium bromide stained
15 1.5% agarose gels were captured using an EagleEye system and EagleSight software (Stratagene). Position control amplifications were performed using the appropriate NAALAD-ase DNA construct. Negative control amplifications contained reaction mix, enzyme and no
20 DNA template. Positive and negative control reactions were performed for 35 cycles. Arrows highlight a specific size in bp as determined using a 100 bp ladder.

25 Figure 14: is an illustration of RT-PCT analysis of NAALAD-ase expression in brain areas. PCR amplifications for 25, 30 and 35 cycles, with primers specific for human NAALAD-ase I (A), L (B), II (C) and IV (D) or GAPDH (E) were performed on normalised human
30 cDNAs prepared from dissected brain areas. Images from ethidium bromide stained 11.5 % agarose gels were captured using an EagleEye system and EagleSight software (Stratagene). Results from 30 and 35 cycles of amplification are shown. Positive control
35 amplifications were performed using the appropriate NAALAD-ase DNA construct. Negative control amplifications contained reaction mix and enzyme with

- 16 -

no DNA template. All control reactions were performed for 35 cycles. Arrows highlight a specific size in bp as determined from the 100 bp ladder.

5 Figure 15: is an illustration of RT-PCR analysis of
NAALAD-ase expression in prostate tumour cells. PCR
amplifications with primers specific for human NAALAD-
ase I (A), L (B), II (C) and IV (D) or GAPDH (E) were
performed on normalised cDNAs prepared from cell lines
10 derived from prostate tumours or on prostate tumour.
Images from ethidium bromide stained 1.5 % agarose
gels were captured using an EagleEye stem and
EagleSight software (Stratagene). Results from 25, 30
and 35 cycles of amplification were shown. Positive
15 control amplifications were performed using the
appropriate NAALAD-ase DNA construct. Negative control
amplifications contained reaction mix and enzyme with
no DNA template. All control reactions were performed
for 35 cycles. Table 1.

20 Native Taq polymerase and PCR buffer with $MgCl_2$, the
Expand_{TM} long template PCR system, ampicillin, IPTG
(isopropyl- β -D-thiogalactoside), X-gal (5-bromo-4-
chloro-3-indolyl- β -D-galactopyranoside) and all
25 restriction enzymes used were from Boehringer Mannheim
(Mannheim, Germany). Super Taq polymerase was from HT
Biotechnology (Cambridge, UK). 10 mM dNTP mix was
purchased from Life Technologies (Gaithersburg, MD,
USA). The original TA cloning kit and the expression
30 vector pcDNA-3 were purchased from Invitrogen BV
(Leek, The Netherlands). The Qiagen plasmid mini- and
maxi- DNA purification kits, the Qiaquick gel
extraction kit and the Qiaquick PCR purification kit
were purchased from Qiagen GmbH (Düsseldorf, Germany).
35 Marathon_{TM} Ready cDNA kits, MTN cDNA panels and MTN
Northern blots were obtained from Clontech
Laboratories (Palo Alto, CA, USA). The QuickChange_{TM}

- 17 -

Site-Directed Mutagenesis Kit was purchased from Stratagene GmbH (Heidelberg, Germany). All PCR reactions were performed in a GeneAmp PCR system 9600 cyclor (Perkin Elmer, Foster City, CA, USA). LB (Luria-Bertani) medium consists of 10 g/l of tryptone, 5 g/l of yeast extract and 10 g/l of NaCl. 2x YT/ampicillin plates consist of 16 g/l of tryptone, 10 g/l of yeast extract, 5 g/l of NaCl, 15 g/l of agar and 100 mg/l of ampicillin.

Expressed sequence tag clones.

Clone numbers 4190746, 1547649, 3448872, 3608639, 2615389 and 1333965 were ordered from the LifeSeq™ expressed sequence tag (EST) database (Incyte Pharmaceuticals Inc., Palo alto, CA, USA). Samples were delivered as transformed bacterial clones.

Oligonucleotide synthesis for PCR and DNA sequencing. All oligonucleotide primers were synthesised by the β -cyanoethylphosphoramidite chemical method on a PerSeptive Biosystems (Framingham, MA, USA) Expedite MOSS Synthesiser or ordered from Eurogentec (Seraing, Belgium). Insert-specific sequencing primers (15- and 16- Mars) were designed manually. DNA was prepared on Qiagen-tip-20 or -100 anion exchange or Qiaquick spin columns (Qiagen GmbH, Düsseldorf, Germany) and recovered from the columns in 30 μ l TE-buffer (10 mM Tris.HCL, 1 mM EDTA (sodium salt), pH 8.0).

Sequencing reactions were done on both strands using the ABI prism BigDye Terminator Cycle sequencing kit and were run on an Applied Biosystems 377XL sequencer (Perkin Elmer; ABI Division, Foster City, CA, USA). The Sequencher™ software was used for sequence assembly and manual editing (GeneCodes, Ann Arbor, MI, USA).

Cloning and sequence analysis of NAALAD-ase I, L, II

- 18 -

and IV.

Sequence similarity searching for NAALAD-ase like molecules. Using the complete human (Accession no.M99487), rat (Accession no. RNU75973) and mouse (Accession no. AF026380) NAALAD-ase I protein sequences, the complete rat NAALAD-ase L (GenBankTM Accession no AF009921) protein sequence and a partial human NAALAD-ase L protein sequence (GenBankTM Accession no. AF010141) as query sequences, a BLAST (Basic Local Alignment Search Tool; Altschul et al., 1990) search was performed on the WashU Merck expressed sequence tag (EST) database and on a proprietary LifeSeqTM human EST database (Incyte Pharmaceuticals Inc, Palo Alto, CA, USA). Six EST clones with homology to NAALAD-ase I and L were ordered from the Incyte Pharmaceuticals.

Plasmid DNA preparation and sequencing from Incyte clones. Each Incyte bacterial clone was grown overnight at 37°C in 100 ml LB-medium supplemented with 100 µg/ml of ampicillin. Plasmid DNA was prepared using a Qiagen plasmid midi or maxi kit according to the manufacturer's instructions. The DNA inserts of all clones were completely sequenced on both strands. Clone 4190746 contained sequences corresponding to human NAALAD-ase L and also included likely intronic sequences, clones 133965, 1547649, 3448872, 3608639 contained overlapping DNA sequences coding for a novel protein with some similarity to other NAALAD-ases and clone 2615389 contained DNA sequences corresponding to yet another novel protein with some similarity to previously identified NAALAD-ases. The novel protein sequences derived from these clones were termed NAALAD-ase II and NAALAD-ase IV respectively.

35

Cloning of NAALAD-ase I by PCR. Sequence data from human NAALAD-ase I (Accession no.M99487) was used to

- 19 -

design primers to amplify the complete coding sequence of NAALAD-ase I by PCR. Primers used were NAALD1S2 (BamHI) = 5'-CCC GGA TCC GAG ATG TGG ATT CTC CTT CAC GAA AC -3' and NAALD1AS2 (XhoI) = 5'- CCC CTC GAG TTA GGC TAC TTC ACT CAA AGT CTC TGC -3' (restriction sites to be introduced are underlined). PCR amplification was performed using Human Marathon-Ready™ cDNA from prostate in a total reaction volume of 50 µl, containing 1X Expand Long Template™ PCR buffer 2, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers NAALD1S1 (BamHI) and NAALD1AS1 (XhoI), 1 µl of Marathon-Ready™ cDNA and 2.5 U of Expand Long Template PCR mix. Samples were pre-heated at 94°C for 5 min before addition of enzyme. Cycling was for 45 s at 94°C, 1 min at 55°C and 1 min 48 s at 68°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel (wt/vol) in 1X TAE buffer (40 mM Tris-acetate, 1 mM EDTA (sodium salt), pH 8.3) and the most prominent DNA band was excised from the gel and purified with the Qiaquick gel extraction kit (Qiagen GmbH, Düsseldorf, Germany). The resulting 2303 base pair (bp) fragment was cloned into the plasmid vector pCR2.1 using the original TA cloning kit according to the manufacturer's instructions. Approximately 20 ng of purified fragment was ligated to 50 ng of pCR2.1 plasmid DNA with 4 U T4 DNA ligase in a total volume of 10 µl. Ligations were incubated overnight at 14°C. 2 µl of the ligation reaction was transformed into TOP10F' competent cells using heat-shock transformation and plated on 2x YT/ ampicillin plates supplemented with IPTG and X-gal for blue-white screening. Colony screening was performed on 10 white colonies, from which plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit, and then digested with BAMHI and XHOI. Four clones containing an insert of the appropriate size were sequenced fully. All the

- 20 -

clones had at least one mis-sense PCR error. Clone 10.0 with a single PCR error at position 1183 was used as the template for a site directed mutagenesis (SDM) reaction using the QuickChange™ SDM Kit. Reactions were carried out according to the manufacturer's instructions. Primers designed for the amplification reactions were NAALD1-SDM-S1 = 5'-CCC TCA GAG TGG AGC AGC TGT TGT TCA TGA AAT TGT GAG G -3' and NAALD1-SDM-AS1 = 5' - CCT CAC AAT TTC ATG AAC AAC AGC TGC TCC ACT CTG AGG G -3'. Three white clones from the SDM transformations were screened. Plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit, digested with BamHI and XhoI and sequenced around the mutation site. A single clone (cl.2.0) was sequenced fully on both strands to confirm the complete correct NAALAD-ase I sequence.

Cloning of NAALAD-ase L by PCR and 5' rapid amplification of cDNA ends (RACE) PCR. Sequence data from partial human NAALAD-ase L (GenBank Accession no.AF10141) was used to design primers to amplify the 3' end of NAALAD-ase L by PCR. Primers used were NAALD2S1 = 5'- GTT CTT CAA CAA GCT GCA GGA GCG -3' and NAALD2AS1 (XhoI) = 5'- CCC CTC GAG CCG GAG TAA AGG GAG GGC TGA AG -3'. Human Marathon-Ready™ cDNA from brain, fetal brain, prostate, small intestine, colon were used in the amplification reactions. First round PCR amplification was performed in a total reaction volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers NAALD2S1 and NAALD2AS1, 1 µl of Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 45 s at 94°C, 1 min at 58°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE

- 21 -

buffer. Second round PCR amplification was performed with nested primers NAALD2S2 = 5'-GGC GAC CTG AGC ATC TAC GAC AAC -3' and NAALD2AS2 (XhoI) = 5'-CCC CTC GAG TCC CCT CAG AGG TCA GCC ACA G -3'. 1 μ l of the

5 first round amplification reaction in a total volume of 50 μ l containing 1X Expand High FidelityTM PCR buffer, 0.2 mM of each dNTP, 0.2 μ M each of oligonucleotide primers NAALD2S2 and NAALD2AS2 and 2.5 U of Expand High Fidelity PCR mix. Samples were

10 preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 45 s at 94°C, 1 min at 57°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1 % agarose gel in 1X TAE buffer and the most prominent

15 DNA bands were excised from the gel and purified with the Qiaquick gel extraction kit. The resulting fragments 600-800 bp were cloned into CR2.1 as described previously. Ligations were incubated overnight at 14°C and transformed into TOP10F'

20 competent cells and plated on 2x YT / ampicillin plates supplemented with IPTG and X-gal for blue-white screening. Colony screening was performed on five white colonies from each transformation. Plasmid DNA was prepared from these colonies using the Qiagen

25 plasmid mini DNA purification kit and then digested with EcoRI. Plasmids containing inserts of the appropriate size were end sequenced using vector primers and then the full sequencing on both strands of putative NAALAD-ase L clones was performed. Clone

30 6.9 derived from small intestine extended to the translation termination codon.

To obtain unknown 5' coding sequence for human NAALAD-ase L, two anti-sense primers were designed for 5' rapid amplification of cDNA ends (5' RACE). The

35 primers were NAALD2AS3 = 5' - GCC AGC ACC CAG AGA ACC CAA G -3' and NAALD2AS4 = 5'-GCT GCG GTT GAA GTA CCG GAT C -3'. Human Marathon-ReadyTM cDNA from brain,

- 22 -

fetal brain, prostate, small intestine and colon were used for the 5' RACE according to the manufacturer's instructions. The Marathon-Ready™ cDNA was prepared using oligo-dT priming and a Marathon cDNA adaptor (including two different adaptor-primer annealing sites) ligated to the 5' end of the cDNA. Adaptor-primer AP1 (5' - CCA TCC TAA TAC GAC TCA CTA TAG GGC - 3') and nested adaptor-primer AP2 (5' - ACT CAC TAT AGG GCT CGA GCG GC -3') were included in the kit.

First round PCR amplification was performed in a total reaction volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP1 and NAALD2AS3, 5 µl of Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 58°C and 2 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE buffer. Second round 5' RACE was performed using 1 µl of the first round amplification reaction in a total volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP2 and NAALD2AS4 and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 57°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were excised from the gel and cloned into the vector pCR2.1 as described earlier. Colony screening by PCR was performed on 60 white colonies in 45 µl PCR mix containing 1X PCR buffer with MgCl₂, 0.2 mM dNTP, 0.5 µM each of vector primer M13FOR (5'- TGT AAA ACG ACG GCC AGT -3') and M13REV (5' - CAG GAA ACA GCT ATG ACC -3') and 0.35 U of super Taq DNA polymerase. Colonies were picked from the plates, inoculated into 100 µl LB medium supplemented with 100 µg/ml of

- 23 -

ampicillin and incubated for 1 hr at 37°C. 5 µl of the incubated culture was then added to 45 µl PCR mix. PCR was performed for 30 cycles (45 s at 95°C, 1 min at 48°C and 50 s at 72°C). 20 µl of the PCR reactions was
5 analysed on 1% agarose gel in 1x TAE buffer. Clones containing inserts were grown overnight in 3 ml LB medium supplemented with 100 µg/ml of ampicillin and plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit. From the 51 clones sequenced
10 one clone 4.10 contained 258 bp of sequence 5' to NAALD2AS4 of which 70 bp were novel. The 5' RACE clone (cl. 4.10) and 3' PCR clone (cl. 6.9) were both digested with BamHI. The digested material was run on 1 % agarose gel in 1X TAE
15 buffer. Two bands were excised, a 336 bp band from cl. 4.10 containing all additional 5' RACE DNA sequences and a ~4700 bp fragment containing the remaining 3' NAALAD-ase L and vector sequence from cl. 6.9. The gel slices were purified with the Qiaquick gel
20 extraction kit. The larger of the two fragments was dephosphorylated with 1.5 U calf of intestinal alkaline phosphatase for 1 hr at 37°C and then heat inactivated for 20 min at 75°C, in order to prevent the self ligation of the fragment with itself.
25 Ligations were performed as described previously and 2µl of the reaction mixture transformed into 35 µl DH10b electrocompetent cells by electroporation (single pulse; 2500V, 25µF 201 W, 5 ms). The electroporated sample was added to 1 ml SOC media and
30 incubated for 1 hr at 37°C before 100 µl of the culture was plated on to 2 x YT/ampicillin plates. Colonies were picked the following day, plasmid DNA prepared and tested by restriction digest. A single clone (cl. 2.0) was fully sequenced on both strands
35 and found to contain the complete 3' coding sequence and the additional sequence from the first 5' RACE reactions. To obtain additional 5' coding sequence

- 24 -

for the human NAALAD-ase L, two new anti-sense primers were synthesised corresponding to sequences from Incyte clone number 4190746. Primers used were NAALD2AS5 = 5'- CTG CAG CTT GTT GAA CTC TTC TGT G -3' and NAALD2AS6 = 5' CAA ACA CGA TTG ATC TGC GAG GAC -3'. Human Marathon-Ready™ cDNA from brain, fetal brain, prostate, small intestine, colon and heart were used for the 5' rapid amplification of cDNA ends (5' RACE) according to the manufacturer's instructions.

First round PCR amplification was performed in a total reaction volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP1 and NAALD2AS5, 5 µl of Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 58°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.3). Second round PCR amplification was performed using 1 µl of the first round amplification reaction in a total volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP2 and NAALD2AS6 and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 75°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1 % agarose gel in 1X TAE buffer and the 8 most prominent DNA bands were excised from the gel and purified with the Qiaquick gel extraction kit. The resulting fragments (400-1300bp) were cloned into the plasmid vector pCR2.1 using the original TA cloning kit. Ligations and transformations were performed as described earlier before plating on 2x YT / ampicillin plates supplemented with IPTG and

- 25 -

X-gal for blue-white screening. Colony screening was performed on five white colonies from each transformation. Plasmid DNA was prepared from these colonies using the Qiagen plasmid mini DNA kit and
5 digested with EcoRI. Plasmids containing inserts of the appropriate size were end sequenced using vector primers and then the full sequence of putative NAALAD-ase L clones was determined using primer walking. The DNA sequence of five clones, from a
10 small intestine cDNA, extended the coding sequence for NAALAD-ase L in the 5' direction beyond the putative translation start codon and included part of the 5' untranslated region. One of these clones one (cl. 2.2) was used for further experiments.

15 To construct a full length NAALAD-ase L clone, two new primer sets were designed to introduce a unique restriction site (Mun I) into the DNA sequence of NAALAD-ase L without resulting in a change in amino acid sequence or frame shift in the open reading frame
20 (ORF). The first primer set was NAALD2S3 (EcoRV) = 5'-CGG ATA TCC GCA GGA TGC AGT GGA CGA AG -3' and NAALD2AS8 (MunI) - 5'- CAA ACA CAA TTG ATC TGC GAG GAC GC -3' and the second primer set was NAALD2S8 (MunI) = 5'- GCG TCC TCG CAG ATC AAT TGT GTT TG -3' and
25 NAALD2AS1 (XhoI). PCR amplification was performed on 1 µl cl. 2.0 plasmid DNA with primers NAALD2S3 (EcoRV) and NAALD2AS8 (MunI) or on 1 µl cl. 2.2 plasmid DNA with primers NAALD2S8 (MunI) and NAALD2AS1 (XhoI). Total reaction volumes were as previously described.

30 Samples were preheated at 94°C for 5 min before addition of the Expand High Fidelity enzyme. Cycling was for 45 s at 95°C, 1 min at 57°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1 % agarose gel in 1X
35 TAE buffer and TA cloned into pCR2.1 as previously described.

- 26 -

Splice variant analysis of NAALAD-ase L.

In PCR reactions using NAALAD-ase L specific primers, a number of amplified PCR products were observed of unexpected size. These PCR reactions were repeated
5 using a number of different cDNAs and bands were excised and purified prior to original TA cloning, as described previously. Plasmid DNA was prepared from these clones and inserts were fully sequenced on both strands in order to identify possible splice variants.

10

Cloning of NAALAD-ase II by PCR and 5' rapid amplification of cDNA ends (RACE) PCR.

Sequencing results from Incyte clone 3608639 suggested that this clone contained DNA sequence spanning the
15 complete coding sequence, 2220 bp in size, of a putative NAALAD-ase like molecule (NAALAD-ase II) that had similar sequence to NAALAD-ase I and L. To confirm that there was no possible initiation codon upstream of the initiation codon already determined 5' RACE PCR was performed. Two anti-sense primers were
20 designed for 5' RACE based on the sequence derived from the clone 3608639, NAALD3AS1 = 5' - CTT TGA TGA TAG CGC ACA GAA GTG G -3' and NAALD3AS2 = 5' GGA AAG ATG CCA GCG CAG GAC 03'. Human Marathon-Ready™ cDNA
25 from brain, foetal brain, prostate, small intestine and colon were used for the 5' RACE according to the manufacturer's instructions. First round PCR amplification was performed in a total reaction volume of 50 µl containing 1X Expand High Fidelity™ PCR
30 buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP1 and NAALD3AS1, 5 µl of Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s
35 at 94°C, 30 s at 58°C and 2 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. Second round 5' RACE was performed using 1 µl of the first round

- 27 -

amplification reaction in a total volume of 50 μ l containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 μ M each of oligonucleotide primers AP2 and NAALD3AS2 and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 57°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE buffer and the most prominent DNA bands were excised from the gel and purified with the Qiaquick gel extraction kit. The resulting fragments (250 - 600 bp) were cloned into the plasmid pCR2.1 as described previously. 32 white colonies were grown overnight in 3 ml LB medium supplemented with 100 μ g/ml of ampicillin and plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit. No upstream initiation codon was identified from any of the 32 clones analysed.

20 Cloning of NAALAD-ase IV by PCR.
Sequencing results from Incyte clone 2615389 revealed that this clone contained partial coding sequence and 3' UTR, of another putative NAALAD-ase like molecule (NAALAD-ase IV) that was related in sequence to

25 NAALAD-ase I, L and II. The DNA sequence obtained was used in a BLAST search on the Incyte LifeSeq™ EST database. One contig (2519841) was assembled from 150 overlapping Incyte EST sequences that spanned 1881 bp and contained a coding region of 1419 bp. The sequence

30 data from human NAALAD-ase IV contig 2519841 was used to design primers to amplify the complete coding sequence of by PCR. Primers used were NAALD4SP2 = 5'-CGT CAG AGC CGC CCT ATC AGA TTA TC -3' and NAALD4AP4 = 5'-GAG GAG TTT TCC AAA GTT GCA GAC CC -3'. PCR

35 amplification was performed using a human hippocampal cDNA in a total reaction volume of 50 μ l, containing 1X Expand High Fidelity™ PCR buffer, 0.2mM of each

- 28 -

dNTP, 0.2 μ M each of oligonucleotide primers NAALD4SP2 and NAALD4APA4, 1 μ l of cDNA and 2.5 U of Expand High FidelityTM PCR mix. Samples were pre-heated at 95°C for 5 min before addition of enzyme. Cycling was for 5 45 s at 94°C, 1 min at 58°C and 35 s at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE buffer and the most prominent DNA band was excised from the gel and purified with the Qiaquick gel 10 extraction kit. The resulting 1544 bp DNA fragment was sub-cloned into the plasmid vector pCR2.1-TOPO using the TA TOPO cloning it according to the manufacturer's instructions. Approximately 10 ng of purified fragment was ligated to 10 ng of pCR2.1-TOPO 15 plasmid DNA. Ligations were incubated for 5 min at 25°C. Transformations into TOP10F' competent cells and colony screening was performed as previously described. Three clones containing an insert of the correct size were sequenced fully and two clones were 20 found to contain no PCR errors (cl. 28.0 and cl.1.0).

Activity determinations of NAALAD-ases transiently expressed in COS cells.

Sub-cloning of NAALAD-ases into expression vectors.

25 NAALAD-ase I, L, II and IV clones were each sub-cloned into the cytomegalovirus (CMV) promoter-based plasmid vector pCDNA-3. NAALAD-ase I/pCR2.1 (cl.2.0) was digested with BamHI/XhoI to excise the complete NAALAD-ase I sequence. NAALAD-ase L-5'/pCR2.1 30 (cl.2.0) was digested with EcoRV/MunI and NAALAD-ase II-3'/pCR2.1 (cl.2.2) was digested with MunI/XhoI to excise the two halves of complete NAALAD-ase L sequence. NAALAD-ase II/pINCYTE was digested with EcoRI to excise the complete NAALAD-ase II sequence. 35 NAALAD-ase IV/pCR2.1 (cl.28.0) was digested with HindIII/XbaI to excise the complete NAALAD-ase IV sequence. Fragments were gel-purified and sub-cloned

- 29 -

into dephosphorylated pcDNA3 that had been previously digested with the appropriate restriction enzymes. The resulting expression constructs were verified by complete sequence analysis as described earlier.

5

Transient transfection into COS cells.

COS cells were maintained in complete medium (DMEM supplemented with 10% foetal calf serum, 1X non-essential amino acids and a 1X

10 strptamycin/penicillin/glutamine mix). Prior to transfection cells were washed twice with PBS, $\text{Ca}^{+2}/\text{Mg}^{+2}$ free pre-warmed to 37°C and dissociated from culture plates by addition of a trypsin/EDTA solution for 1-2 minutes. Cells were collected after a 10 min
15 spin at 1600 rpm and re-suspended in 1-2 ml of equilibrated (5% CO_2 /95% air) pre-warmed medium. The cell titre was determined in a Coulter counter and cells were seeded in 6 well plates at a density of 15000 cells/cm² and allowed to reach approximately 80%
20 confluence (~2 days growth). For each transfection 6 µl FuGENE6 (Boehringer Mannheim, Germany) was added to 96 µl serum free medium and incubated for 5 minutes at 20°C. This preparation was added to a second tube containing 1 µg of NAALAD-ase/pcDNA3 DNA, mixed gently
25 and allowed to stand for 15 minutes at room temperature. The DNA/FuGENE6/serum-free medium mix was pipetted into a well containing 2 ml fresh complete medium. Cells were incubated for 72 hrs in a 37°C incubator before collection.

30

Determination of Biological Activity of NAALAD-ase homologues.

NAALAD-ase activity was quantified by determination of the extent of hydrolysis of N-acetyl-L-aspartyl-L-
35 (3,4-[³H])-glutamate as previously described (Blakeley et al., 1988). Transfected COS cell pellets were incubated with 50 mM Tris-HCl (pH7.4)/0.1% Triton X-

- 30 -

100 and vortexed. Homogenates were put through at least one freeze/thaw cycle in liquid N₂ before being used for assay. All assays were formed in a total volume of 200 µl containing 50 mM Tris-HCl (pH 7.4), 1 mM Zn²⁺Cl₂, 500 nM N-acetyl-L-aspartyl-L-(3,4-3[H])-glutamate ([³H]-NAAG) and 10-200 µg membrane protein in the presence or absence of 3µM quisqualate / 1% DMSO (vol/vol). Assays were initiated by the addition of the membrane homogenates to the assay mixture, preincubated at 37°C. The assay mixture was vortexed and incubated at 37°C for various time points. Reactions were terminated by addition of 200 µl ice cold 250 mM potassium phosphate and placing the reaction tubes in ice water. After a 5 min centrifugation step at 14000 rpm, the assay samples were loaded onto 4 cm anion exchange mini-columns (Bio-Rad Ag1-X 8) that had been pre-washed with MilliQ water. Columns were rinsed twice with 2 ml MilliQ water, and then twice with 2 ml of 0.5 M formic acid to selectively elute the [3H]-glutamate. The remaining substrate could be eluted with 7.5M formic acid. Assay eluates were diluted with scintillation cocktail (16 ml Ultima Gold XR) and counted in a scintillation counter (Packard). Blanks (not exposed to membranes) were always subtracted. Inhibition curves were performed under similar conditions with concentrations of quisqualate (QA) ranging up to 300 µM. Reactions were followed for 30 min for NAALAD-ase I and for 60 min for NAALAD-ase L and II prior to termination of the reaction.

SPA development for high throughput screening. NAALAD-ase assays were performed at 37°C or 25°C for 10 min in the presence of 50 mM Tris-HCl, pH 7.4, containing 1 mM ZnCl₂. Each assay was performed in a 100 µl reaction volume containing 40 nM 3[H] -NAAG, 50 mM Tris-HCl (pH 7.4), 1 mM Zn²⁺Cl₂ and either 10 µg of

- 31 -

recombinant NAALAD-ase I or LNCaP cell membrane preparations. Reactions were terminated by addition of 100 μ l glycine buffer (pH 3.0) and 1 mg naked YS-SPA beads. After allowing the beds to settle for 30 min, the assay mixture was counted in a microtiterplate scintillation counter.

Chromosomal localisation of NAALAD-ases by FISH.

Chromosomal mapping studies were carried out by Sidney Biotech Inc (North York, Ontario Canada) using fluorescent *in situ* hybridisation (FISH) analysis.

Slide preparation. Lymphocytes isolated from human blood were cultured in α -minimal essential medium (MEM) supplemented with 10% foetal calf serum and phytohaemagglutinin at 37°C for 68-72 h. The lymphocyte cultures were treated with BrdU (0.18 mg/ml, Sigma Chemical Company, St.Louis, MO, USA) to synchronise the cell population. The synchronised cells were washed three times with serum-free medium to release the block and re-cultured at 37°C for 6 h in α -MEM with thymidine (2.5 μ g/ml, Sigma). Cells were harvested and slides were prepared using standard procedures including hypotonic treatment, fixation and air-drying.

FISH detection: Probes (NAALAD-aseI/pCR2.1 (cl. 2.0) cut with BamHI/XhoI; NAALAD-aseL/pCR2.1 (cl.2.0) cut with XhoI; NAALAD-aseII/pcDNA3 (cl. 3.0) cut with HindIII/XbaI; NAALAD-aseIV/pCR2.1 (cl. 28. 0) cut with HindIII/XbaI; were biotinylated with dATP for 1 h at 150C using the BioNick labelling system (Life Technologies, Gaithersburg, MD, USA). The procedure for FISH detection was performed as previously described (Heng et al, 1992; Heng & Tsui, 1993). Slides were baked at 55°C for 1 h. After RNase treatment, the slides were denatured in 70% formamide

- 32 -

in 2x SSC (20x SSC being 3 M NaCl, 0.3 M sodium citrate, pH 7.0) for 2 min at 70°C followed by dehydration with ethanol. Probes were denatured at 75 C for 5 min in a hybridisation mix consisting of 50%
5 formamide and 10% dextran sulphate. Probes were then loaded on the denatured chromosomal slides. After overnight hybridisation, slides were washed and detected. FISH signals and the DAPI-banding pattern were recorded separately by taking photographs, and
10 the assignment of the FISH mapping data with chromosomal bands was achieved by superimposing FISH signals with DAPI banded chromosomes.

Tissue Distribution of NAALAD-ases.

15 Northern Blot Analysis for NAALAD-ase II and IV.
Human MTN Northern blots containing 2µg of poly (A) + RNA derived from non-neuronal tissues were hybridised in ExpressHyb_{TM} hybridisation solution for 2 to 3 h at 68°C according to the manufacturer's instructions. A
20 546 bp NAALAD-ase II fragment was isolated from NAALAD-ase II/pcDNA3 (cl. 3.0) following digestion with EcoRI and BglII and a NAALAD-ase IV 526 bp fragment was isolated from NAALAD-ase IV/pCR2.1-TOPO (cl. 28 .0) following digestion with PstI.
25 Radiolabelled probes were generated with these DNA fragments using a Rapid Multiprime Labelling kit and [³²P] - dCTP as label. Following removal of unincorporated label using a Micospin S-200 HR column (Pharamcia), 50 µl of hot denatured probe in 6 ml
30 ExpressHyb_{TM} hybridisation solution was incubated in a rotating shaker at 68 C overnight. Washes were 4 x 15 min RT in 2X SSC/0.05% SDS, 1 X 20 min wash at 50 C in 0.1X SSC/0.1% SDS and 2 X 20 min at 55 C in 0.1X SSC/0.1% SDS and 2 X 20 min. Blots were wrapped in
35 cling flim, without drying and exposed to X-omat AR Scientific Imaging Flim (Kodak Scientific Imaging Systems, Cambridge, UK) for 2 to 4 days at -70°C with

- 33 -

two intensifying screens.

Gene Expression of NAALAD-ase I, L, II and IV by RT-PCR analysis.

- 5 Oligonucleotide primers designed for the specific amplification of a PCR fragment for each NAALD-ase; NAALAD-ase I primers were NAALAD1S3 5' - GGG AAA CAA ACA AAT TCA GCG GC - 3' and NAALD1AS3 5' GTC AAA GTC CTG GAG TCT CTC ACT GAA C - 3' yielding a 341 bp
- 10 product, NAALAD-ase L primers were NAALD2S7 5' - GAC CGG AGC AAG ACT TCA GCC AG - 3' and NAALD2AS7 5' - GTG TTG ATA TGC GTT GGC CCA AG - 3' yielding a 330 bp product, NAALAD-ase II primers were NAALD3S4 5' CAC TAA GAA TAA GAA AAC AGA TAA GTA CAG C-3' and NAALD3AS4
- 15 5'-GAT CAA CTT GTA TAA GTC GTT TAT GAA AAT CTG - 3' yielding a 353 bp product and NAALAD-ase IV primers were NAALD4S1 5' - GCA GAA GAA CAA GGT GGA GTT GGT G-3' and NAALD4AS1 5' - GCT TTG GAT CCA TGA CAG TCA TGG - 3' yielding a 336 bp product. Each primer set for
- 20 each NAALAD-ase was tested for its ability to specifically amplify that NAALAD-ase and not to cross react in amplification reactions with the other three forms. PCR amplifications for human GAPDH were performed on the same cDNA samples as positive
- 25 controls using GAPDH specific primers 5'-TGA AGG TCG GAG TCA ACG GAT TTG GT-3' (sense primer) and 5'- CAT GTG GGC CAT GAG GTC CAC CAC-3' (anti-sense primer), yielding a 1000 bp fragment. These primers sets were used for PCR amplifications on human multiple tissue
- 30 cDNA (MTCTM) panels normalised to the mRNA expression levels of six different housekeeping genes. Human cDNAs from 15 brain regions were also prepared from mRNA and normalised to the mRNA expression levels of three different housekeeping genes, GAPDH, clathrin
- 35 and actin. Brain area mRNA was prepared starting from carefully dissected tissue samples, using the FastTrackR 2.0 kit (Invitrogen BV, Netherlands)

- 34 -

according to the manufacture's instructions. 1 μ g of poly (A) + RNA was reverse transcribed using oligo (dT) 15 as a primer and 50 U of ExapndTM Reverse Transcriptase (Boehringer Mannheim, Germany) according to the manufacturer's instructions. Finally, normalised cDNA was prepared in a similar manner from 3 transformed prostate tumour cell lines and a prostate tumour. PCR reactions with NAALAD-ase or GAPDH specific primers were performed on 2 or 5 μ l of cDNA. PCR reactions were performed in a total volume of 50 μ l in 1X Advantage PCR buffer, 0.2 mM dNTP and 0.5 μ M of each PCR primer and 1 μ l Advantage Taq polymerase mix (95°C -30 sec, 68°C - 1 min 30 s for 35 cycles). Upon completion of 25 cycles the PCR machine was paused at 80C, reaction tubes were removed and 15 μ l were removed from each PCR tube. Tubes were then returned to the machine and the cycling method continued. Aliquots were removed in a similar manner after 30 and 35 cycles. Each sample taken was analysed by 1.0% agarose gel electrophoresis as previously described and images of the ethidium bromide stained gels were obtained using an Eagle Eye II Video system (Stratagene, La Jolla, CA, USA).

25 Results

Molecular cloning and sequence analysis of NAALAD-ase II, L and IV.

NAALAD-ase L; Similarity searching of the Incyte LifeSeqTM database with the human, rat and mouse NAALAD-ase I sequences and with rat and partial human NAALAD-ase L protein sequences yielded 13 EST sequences, some of which were overlapping, encoding for putatively novel protein sequences similar to NAALAD-ase I and L. DNA obtained from six of the most 5' clones were sequenced.

Incyte clone 4190746, from a cerebellar cDNA library contained sequences corresponding to NAALAD-ase L.

- 35 -

However, since this clone also contained two segments of intronic sequence it was not suitable for further cloning experiments. PCR reactions were performed to amplify a PCR product containing the 3' half of the

5 NAALAD-ase L coding region from a small intestine cDNA. To identify the remaining as yet unknown human 5' NAALAD-ase L sequence, 5' RACE PCR was performed on a number of cDNAs. Sequencing of the amplification

10 products obtained from reactions using small intestine cDNA yielded a further 1344 bp fragment covering the complete coding sequence of NAALAD-ase L. The full cDNA sequence contained an open reading frame of 2223 bp encoding a protein of 740 amino acid residues with a calculated molecular mass of 80.6 kDa and an

15 isoelectric point of 5.26 (Fig.1). The putative ATG translation start codon is in a favourable context for translation initiation (Kozak, 1989) with no ATG codons detected upstream. Analysis of the human NAALAD-ase L ORF predicted a type II integral membrane

20 protein containing a single hydrophobic membrane-spanning domain extending from amino acid residues 6-27, with lysine residues bordering either side of the potential membrane-spanning domain (determined by the method of Kyte-Doolittle, 1982). There are 7

25 potential N-glycosylation sites (N X S/T), indicated in Figure 1. The predicted protein sequences of human NAALAD-ase L was compared to that of rat using the alignment program Genedoc. Human NAALAD-ase L sequence was 78% identical and 87% similar to rat

30 NAALAD-ase L. The two protein sequences were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany; Fig.2)

NAALAD-ase II; Incyte clones 1547649, 3448872,

35 3608639 and 1333965 contained sequences originating from the same gene that were similar to but not identical to NAALAD-ase I or L. Clone 3608639, from a

- 36 -

lung carcinoma cDNA library, contained a 3110 bp DNA sequence, with a 2223 bp ORF coding for a 740 amino acid residue protein, which we termed NAALAD-ase II (Fig.4). Analysis of this open reading frame

5 predicted a calculated molecular mass of 83.6kDa and an isoelectric point of 8.53. The putative ATG translation start codon is in a favourable context for translation initiation (Kozak, 1989) and no ATG codons were detected upstream. NAALAD-ase II was predicted

10 to be a type II integral membrane protein containing a hydrophobic membrane spanning domain extending from amino acid residues 8-31 (determined by the method of Kyte and Doolittle, 1982). There are also 7 potential N-glycosylation sites (N X S/T) indicated in Fig.4.

15

NAALAD-ase IV; Sequencing of Incyte clone 2615389, derived from a gall bladder cDNA library, identified sequences originating from a gene with some similarity to NAALAD-ase I and L. Homology searching in the

20 Incyte EST database using this new sequence information identified a contig of over 150 overlapping EST sequences spanning 1884 bp and containing an ORF of 1419 bp, plus 5' and 3' UTRs. Translation of the ORF predicted a 472 amino acid

25 protein with calculated molecular mass of 51.9 kDa and an isoelectric point of 5.99 (Fig.5). We have named this protein NAALAD-ase IV. The putative ATG translation start codon is in a favourable context for translation initiation with no ATG codons detected

30 upstream. Analysis of the NAALAD-ase IV sequence predicted a type II integral membrane protein containing a hydrophobic membrane spanning domain extending from amino acid 3 to approximately 24 with lysine residues found on either side of the potential

35 membrane-spanning domain (determined by the method of Kyte and Doolittle, 1982). There are 5 potential N-glycosylation sites (N x S/T) indicated in Fig. 5.

- 37 -

The predicted protein sequences of NAALAD-ase I, L, II and IV were compared to each other using the alignment program BESTFIT (Wisconsin package, Genetics Computer Group Software, Madison, Wisconsin, USA). The % identity and % similarity between each pair of sequences calculated by the Genedoc program is indicated in Table 1. NAALAD-ase I sequence was 67% identical to NAALAD-ase II, 35% identical to NAALAD-ase L and 10% identical to NAALAD-ase IV. NAALAD-ase L and II were 37% identical. The four protein sequences for NAALAD-ase I, II, L and IV were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany) and are shown in Fig. 6. The highest regions of conservation between these proteins occur in the two predicted catalytic domains. A phylogram of NAALAD-ase I, II, L and IV was constructed using GCG 'Distances' program with standard parameters and the 'Growtree' program with the UPGMA method and is depicted in Fig. 7. From this phylogram it is clear that NAALAD-ase I and II are the most closely related proteins with NAALAD-ase IV being the distant relative.

Two putative catalytic domains have been identified in NAALAD-ase I and L sequences by comparison to other peptidases (Bzegda et al., 1997; Shneider et al., 1997). Using multiple sequence alignments of NAALAD-ase I, II, L and IV we have identified similar putative catalytic domains in human NAALAD-ase II, L and IV (see Fig. 6 and 8). The first catalytic domain is related to bacterial and yeast Zn^{2+} dependent peptidase domains (Bzegda et al., 1997). Alignments of these peptidases with NAALAD-ases I, II, L and IV are shown in Fig. 8. All five residues important in Zn^{2+} binding are conserved in the NAALAD-ase family. Additionally, a Glu residue thought to play a role in catalysis is also present. The NAALAD-ase IV sequence, although more distantly related, also shows

statistically significant similarity to the bacterial and yeast amino-peptides Zn^{2+} binding domain as determined by the Blastp algorithm (~60% similar, $p=10^{-5}$). The second catalytic domain is related to members of the α/β hydrolase fold family of proteins (Shneider et al., 1997). Interestingly, there is a conserved nucleophile-acid-base alignment amongst NAALAD-ase I, II and L that may be important in the enzymes catalytic activity (Goossens et al., 1995). Rat NAALAD-ase L has been suggested to belong to an α/β hydrolase fold family of peptidases, similar to dipeptidyl peptidase IV (DPPIV). In contrast, NAALAD-ase IV which is about 270 residues shorter than the other NAALAD-ase proteins lacks this domain.

15

Alternative splicing of NAALAD-ase L.

In the course of the cloning and RT-PCR gene expression analysis of NAALAD-ase L a number of amplified PCR products were observed, isolated and sequenced in order to identify possible splice variants. We found both the splicing out of putative exon sequences, as well as the presence of intronic sequences, as judged by the presence of GT/AG donor/acceptor sites, that were repeatedly amplified from our cDNA preparations (Fig. 3). When performing 5' RACE amplifications deletions between bases 497-619 and 903-1007 were identified in small intestine and colon that resulted in two in-frame amino acid deletions. In addition a 153 bp intron was found inserted at base 1094 resulting in an in-frame amino acid insertion of 51 amino acid residues. This insertion is most likely an intron as it has the consensus GT/AG donor acceptor sites at its 5' and 3' ends respectively. In the 3' RACE amplification reactions several variants were also identified in amplifications from small intestine, colon, brain and foetal brain. These consisted of either a deletion of

- 39 -

bases 1525-1615 or a larger deletion between bases 1525-1697. Both these deletions resulted in frame shifts and the premature termination of the protein sequence. Finally, in every cDNA sample examined, two intronic sequences were found to be inserted at either base 1697 and/or at base 1870. Inclusion of one or both of these intronic sequences into the ORF of NAALAD-ase L accounted for the unexpected amplified PCR products migrating at 420 and 500 bp in the RT-PCR experiments. Introduction of one or both these sequences results in a frame shift of the amino acid coding sequence (Fig. 3).

Expression and functional activity of NAALAD-ases. To determine if the newly identified NAALAD-ases had peptidase activity, mammalian expression constructs were transiently transfected into COS cells. Membranes from mock transfections were always prepared in parallel as negative controls. Expression of NAALAD-ase I in COS cells was performed as positive control to establish the working conditions of the assay. Fig.9A shows the amount of [3H]-glutamate in dpms eluted off mini-columns following incubation of [3H]-NAAG with the recombinant NAALAD-ase I. Increasing [3H]-glutamate is eluted from the column in a time dependent manner. Activity was observed for both NAALAD-ase L (data not shown) and NAALAD-ase II (Fig. 9B) suggesting that these enzymes have a similar dipeptidase activity as NAALAD-ase I in this assay. No NAALAD-ase IV dipeptidase activity was observed under these assay conditions. Addition of 30µM quisqualic acid to the reaction inhibited this activity by over 50% after 60 min (Fig. 9A and 9B). Inhibition curves with increasing concentrations of QA were also performed (Fig. 9C) with IC₅₀ values of 1.2 x 10⁻⁵ M and 1.7 x 10⁻⁵ M for NAALAD-ase I and NAALAD-ase II respectively.

- 40 -

A scintillation proximity assay (SPA) was also developed in order to facilitate screening of NAALAD-ase type activity using either the recombinant proteins or membrane preparations from sources known to contain NAALAD-ase activity. A time course of [3H]-NAAG hydrolysis was initially performed using NAALAD-ase I rich LNCaP membrane preparations (Fig. 10A). Stopping the reaction with glycine buffer resulted in binding of the remaining [3H]-NAAG substrate to the SPA beads whereas hydrolysed [3H]-glutamate remained unbound. Therefore as the reaction proceeded and the substrate is hydrolysed, a decrease in signal bound to the beads is observed. Under these SPA conditions, inhibition curves were performed on LNCaP membranes or recombinant NAALAD-ase I membrane preparations using increasing concentrations of QA (Fig. 10B). The IC₅₀ values were 9.1×10^{-7} M for LNCaP preparations and 1×10^{-6} M for NAALAD-ase I preparations.

20

Chromosomal localisation.

The complete coding sequence of NAALAD-ase I was used as a probe for FISH analysis. Under the conditions used, the hybridisation efficiency was approximately 71 % for this probe (among 100 checked mitotic Figures, 71 of them showed signals on one pair of the chromosomes). DAPI banding was used to identify the specific chromosome and an assignment between the signal from the probe and the short arm of chromosome 11 was obtained. The detailed position was further determined based upon summary data from 10 photographs (Fig. 11). A weak hybridisation signal was also detected in the region of 11q14.3 with low frequency. With the mapping data obtained from NAALAD-ase II it was concluded that this weak signal was a result of cross-hybridisation (see later) and that NAALAD-ase I is located solely at human chromosome 11, region

- 41 -

p11.21. Example of the mapping results are presented in Fig. 11. For NAALAD-ase L, a 1059 bp fragment (from pos. 1204-2262bp) was used as a probe for FISH analysis. The hybridisation efficiency was approximately 71 % and DAPI banding was used to identify the signal to the long arm of chromosome 11. The detailed position determined from 10 photographs was on human chromosome 11, region q12 (Fig. 11). For NAALAD-ase II, a 2.5 kb fragment (from pos. 1-2552 bp) was used as a probe for FISH analysis. The hybridisation efficiency was approximately 74% for this probe. DAPI banding was used to identify the signal to the long arm of chromosome 11. The detailed position determined from 10 photographs was on human chromosome 11, region q14.3-q21 (Fig. 11). For NAALAD-ase IV, a 1539 bp fragment (from pos. 1-1539bp) was used as a probe for FISH analysis. The hybridisation efficiency was approximately 72% for this probe. DAPI banding was used to identify the signal to the long arm of chromosome 8. The detailed position (Fig. 11) determined from 10 photographs was on human chromosome 8, region q21.3. Tissue distribution of NAALAD-ase III and IV as determined by Northern blot.

The tissue distribution of TrnR3 in different brain regions and in non-neuronal tissues was investigated using RT-PCR, Northern blot analysis and *in situ* hybridization. Northern blot analysis was performed on mRNA derived from different human tissues (Fig. 12A). A NAALAD-ase II specific probe indicated the presence of transcripts in testis>>>ovary, spleen>prostate, heart and placenta with no signal observed in other tissues. In testis, four transcripts were represented. The most predominant transcript was of approximately 3.4 kb, consistent with the approximate expected size of a NAALAD-ase II message. Two transcripts of 2.4 and 4.4 kb

- 42 -

respectively and a weaker transcript of about 7.5 kb were also present. In the other tissues the 3.4 kb transcript was the only signal detected, apart from ovary where a weak 7.5 kb signal could also be seen.

5 The precise nature of these transcripts awaits further elucidation but may be due to alternative splicing of the message. The nature of these messages is unclear. A NAALAD-ase IV specific probe showed the ubiquitous presence of transcripts in all tissues examined with slightly less signal observed in brain, thymus and testis (Fig. 12B). The most predominant transcript was of approximately 2.2 kb, consistent with the approximate expected size of a NAALAD-ase IV message, with a faint band detected in some tissues at 4.4 kb.

15 Analysis of NAALAD-ase gene expression by RT-PCR. To further examine the detailed tissue distribution of all NAALAD-ases, PCR was performed on normalised cDNAs from 16 different tissues. Figure 13A shows the results from PCR reactions performed with NAALAD-ase I specific primers, yielding amplification products of the expected size (~341 bp). Highest expression of NAALAD-ase I appeared to be in prostate. Rank order of expression after 25 cycles was prostate >>> liver and kidney > small intestine > brain, spleen, with no product amplification observed in the other tissues. At 30 cycles amplification products could be seen in most other tissues with the exception of muscle, blood and thymus in which products could only be observed after 35 cycles of amplification. NAALAD-ase L specific primers yielded a 330 bp amplification product of the expected size, as well as two products migrating with slightly higher sizes of 420 bp and 500 bp (Fig. 13B). NAALAD-ase L expression was highest in small intestine, spleen and testis with PCR products detected after 25 cycles of amplification, whilst products in heart, ovary, colon, blood and prostate

- 43 -

could be seen after 30 cycles. All tissues exhibited some amplification products following 35 cycles with brain and muscle showing the lowest levels. The 420 and 500 bp bands were due to amplification of NAALAD-ase I sequences containing one or two intronic sequences that were commonly found in all our amplification reactions (see earlier). NAALAD-ase II specific primers yielded a 353 bp amplification product of the expected size (Fig. 13C). NAALAD-ase II expression was highest in ovary, testis and spleen with PCR products detected after 25 cycles of amplification. After 30 cycles amplification products could be detected from all tissue cDNAs apart from lung, muscle, blood and thymus in which a product could only be seen after 35 cycles. These results are in good accordance with the expression data obtained with the MTN Northern blots. NAALAD-ase IV specific primers yielded a 336 bp amplification product of the expected size (Fig. 13D). NAALAD-ase IV expression was low in all tissues with amplification products only detected after 35 cycles. Expression levels were comparable in all the cDNAs apart from brain, lung, muscle and thymus in which no amplification products were clearly visible. Control amplification reactions using GAPDH specific primers demonstrated comparable levels of amplification products for each cDNA (Fig. 13E). Comparison of the relative abundance between the four messages was also possible from these experiments, since the same cDNAs were used for each set of amplifications. Abundance of NAALAD-ase I message was greater than NAALAD-ase II which was greater than NAALAD-ase L, as judged by the relative amount of amplification products detected at 25 and 30 cycles. NAALAD-ase IV was expressed at the lowest levels, with PCR products detected only after 35 cycles of amplification. PCR reactions were also performed with the same

- 44 -

NAALAD-ase primers as in the above experiments, on 13 different brain cDNAs normalised to the expression levels of three different housekeeping genes. NAALAD-ase I specific amplification products were detected with highest levels of ventral striatum and brain stem after 30 cycles. After 35 cycles NAALAD-ase I specific amplification products could clearly be detected in all brain areas studied (Fig. 14A). NAALAD-ase L specific primers yielded a 330 bp amplification product of the expected size, as well as a product migrating at a higher size of 500 bp (Fig. 14B). Amplification of the 500 bp product was observed after 35 cycles in brain stem, amygdala, thalamus, ventral striatum and to a lesser extent in striatum and hippocampus, whereas the 330 bp product of the expected size was only seen in brain stem and ventral striatum. NAALAD-ase II specific primers yielded a 353 bp amplification product of the expected size (Fig. 14C). Amplification products were observed after 30 cycles in striatum, parietal cortex and ventral striatum with lower levels of amplification product detected in hippocampus, brain stem, putamen and superior colliculus. After 35 cycles the presence of NAALAD-ase II specific products could be detected in all cDNAs apart from inferior colliculus. NAALAD-ase IV specific products could be detected in all brain cDNAs studied after 30 cycles with little difference observed in expression pattern. Levels of amplification products were slightly higher in striatum, hippocampus, brain stem and ventral striatum (Fig. 14D). Control amplification reactions using GAPDH specific primers demonstrated comparable levels of amplification products for each cDNA apart from brain stem which yielded relatively more GAPDH specific product (Fig. 14E). Overall expression of NAALAD-ase L appears to be lower in these brain areas relative to NAALAD-ase I, II and IV.

Finally, NAALAD-ase expression was investigated in cDNAs prepared from either prostate tumour cell lines or a prostate tumour, that had been normalised against three different housekeeping genes. NAALAD-ase I expression was highest in LNCaP and prostate tumour (Fig.15A). Amplification products were also detected in PC-3 cDNA after 30 and 35 cycles but not in DU145 cDNA. The 330 bp NAALAD-ase L product was detected in highest amounts in cDNA from prostate tumour and less in PC-3 and DU145 samples after 35 cycles (Fig. 15B). Interestingly, in all samples apart from prostate tumour, the higher 500 bp amplification product could be detected. NAALAD-ase II expression was higher in LNCaP than prostate tumour. A faint amplification product could also be detected in PC-3 after 35 cycles but not in DU145 cDNA (Fig. 15C). NAALAD-ase IV expression was highest in LNCaP and prostate tumour (Fig. 15D). Representative amplification with GAPDH primers are also shown (Fig. 15E).

NAALAD-ase I is a type II membrane glycoprotein, with carboxypeptidases activity and sequence similarly to the transferrin receptor (54% identical, Israeli et al., 1993). It may be important in the progression of prostate cancer since it is highly expressed in prostate tumours, and in the CNS it may have an important role in modulating neuronal glutamatergic activity. In this report we describe the identification and cloning of human cDNAs encoding distinct NAALAD-ase enzymes, that represent an expansion of this family of proteins. We have identified in this report two novel members of the NAALAD-ase enzyme family, NAALAD-ase II and NAALAD-ase IV and determined the full coding sequence of human NAALAD-ase L. The degree of divergence of NAALAD-ase L, II and IV at the amino acid sequence level indicates that these are not variants of existing

- 46 -

known genes but new and distinct members of this family. As has been determined for NAALAD-ase I, features common to all three receptors include a hydrophobic leader sequence at the amino-terminus suitable for secretion, and the presence of several possible N-glycosylation sites. All three novel NAALAD-ases contain a single hydrophobic region of approximately 21 to 24 amino acid residues at their amino-terminus, which is likely membrane spanning, a short intracellular domain and a large globular extracellular domain. This structure is typical of type II integral membrane proteins and is common amongst membrane bound hydrolases (Kenny et al., 1982). Sequence alignment comparisons of the four proteins suggests that NAALAD-ase II is most closely related to NAALAD-ase I (81% similar at the amino acid level), whereas NAALAD-ase L is equally similar to both NAALAD-ase I and II (54% similar to both). NAALAD-ase IV is distantly related to the other members of the family.

Analysis of NAALAD-ase L sequences using different PCR primers sets revealed the presence of multiple splice variants and isoforms. The biological significance or alternatively spliced isoforms of NAALAD-ase L awaits further clarification. However, the spliced out residues may affect levels of glycosylation and more importantly the conformation and activity of the protein. Furthermore, inclusion of three different intronic sequences identified in amplification reactions from numerous cDNAs, result in either an in-frame addition of a proline rich, 51 amino acid residue, sequence close to the putative catalytic zinc binding domain, or in frame shifts and subsequent premature termination of the NAALAD-ase L protein.

These premature terminations result in elimination of the predicted nucleophile-acid-base arrangement of the putative catalytic site found in α/β hydrolases and

will result in a gross change in the proteins conformation (see Fig. 3). Inclusion of two of the intronic DNA sequences, resulting in frame shifts and premature protein termination, were identified in
5 nearly all the cDNAs studied, suggesting that expression of these sequences may be used to regulate the levels of active protein. Expression studies using these different splice variants will help to understand the structure/activity relationship of
10 NAALAD-ase L and help identify which amino acid residues within the protein are important for enzymatic activity. A soluble splice variant of NAALAD-ase I has been reported, lacking the first 40 amino acid residues, including the membrane spanning
15 domain (Su et al., 1995). An increased ratio of full length protein to truncated protein was observed in malignant prostate tissues, suggesting that expression of alternative splice variants may correlate with tumour progression. Further work will determine if
20 NAALAD-ase L is involved in oncogenesis and if these splice variants effect tumour progression to differing degrees.

In human tissues, NAALAD-ase I mRNA was highly expressed in prostate but also in liver, kidney and
25 small intestine and to a lesser extent in brain and spleen. This is partial agreement with Northern blot results obtained in rat in which the highest levels of expression were found to be in brain and kidney but not liver or spleen (prostate was not studied; Bzedga
30 et al. 1997; Carter et al., 1998). NAALAD-ase L expression by RT-PCR was highest in spleen, small intestine and testis. Schneider and colleagues (1997) identified a rat ileal 100 kD protein (I-100; rat NAALAD-ase L) expressed in rat ileum and human small
35 intestine as seen by Northern blot, but not in testis or spleen. Discrepancies between NAALAD-ase I and L expression patterns could be attributed either to

species differences or the increased sensitivity of mRNA detection by RT-PCR compared to Northern blot hybridisation. NAALAD-ase II mRNA expression was studied both by Northern blot and RT-PCR experiments.

5 Expression experiments using these methods yielded comparable results with the highest levels of mRNA expression being observed in testis and ovary, with less message in spleen, placenta and heart. A number of differently sized transcripts were observed that

10 hybridised to the NAALAD-ase II probe, suggesting the presence of multiple isoforms. It remains to be determined whether these are due to physiologically relevant smaller transcripts or due to problems with the integrity of the mRNA. NAALAD-ase IV mRNA

15 expression was also studied using both techniques and expression data were consistent between the experiments. NAALAD-ase IV expression appeared to be more evenly distributed amongst tissues, with the highest expression in ovary and little or no

20 expression in brain, lung, thymus and testis. Analysis of NAALAD-ase expression in different human brain areas by RT-PCR suggests that NAALAD-ase L is expressed at lowest levels in these brain areas. The amplification products (except those from ventral

25 striatum) migrating at 500 bp were of a higher than expected size and found to contain intronic DNA sequences (see earlier). NAALAD-ase I, II and IV were expressed at the mRNA level in almost all brain areas studied to differing degrees, with highest expression

30 observed in brain stem, striatum, ventral striatum and putamen. In addition, NAALAD-ase II expression appeared relatively more abundant in frontal and parietal cortex. RT-PCR experiments performed on various prostate tumour cell lines and on a prostate

35 tumour sample agreed with reports showing that NAALAD-ase I is expressed in highest amounts in the androgen receptor positive LNCaP cell line (Israeli et al.,

1993). Some amplification products were also observed in PC-3 cells after 30 and 35 cycles of amplification, in contrast to previous studies detecting no message in the androgen receptor negative cells DU-145 and PC-3 by Northern blotting (Israeli et al. 1993). Since low levels of NAALAD-ase actively have been observed in these latter two cell lines, some expression of these enzymes, including NAALAD-ase I, may occur (Pinto et al., 1996). NAALAD-ase II was also expressed in LNCaP cells at the highest levels, whereas NAALAD-ase IV expression was highest in PC-3 cells. Interestingly, NAALAD-ase L amplification products from LNCaP cells were of a higher than expected size and contained intronic sequences, in contrast to the product observed from prostate tumour. PC-3 and DU-145 cells yielded both the high and low sized amplification products.

Carboxypeptidase activity of NAALAD-ase I has been demonstrated against two classes of substrate *in vitro*. The first is based on the enzymes ability to hydrolyse x-linked acidic peptides such as N-acetylasparyl glutamate (NAAG) or x-glutamylglutamate and the second is based on its ability to hydrolyse γ -linked peptides such as folyl-poly- γ -glutamate or γ -glutamylglutamate. In this study we have expressed NAALAD-ase II, L and IV in COS cells and studied the ability of these recombinant preparations to hydrolyse NAAG. NAALAD-ase I, II and L all showed activity against this substrate that was inhibited by QA.

QAIC50s for NAALAD-ase I and II were determined to be about 10 μ M for both proteins, comparable to that described for NAALAD-ase activity in lysed synaptosomal membranes (Robinson et al., 1987). The X-linked NAALAD-ase hydrolysis of NAAG was initially characterised in membrane preparations from brain and shown to be QA sensitive. Activity was increased by divalent cations and inhibited by divalent metal

chelators or general metalloprotease inhibitors (Robinson et al., 1987; Blakely et al., 1988). It was subsequently shown that the enzymatic activity associated with prostate specific marker (PSM, Carter et al., 1996) and rat brain carboxypeptidase II (Luthi-Carter et al., 1998) following transfection experiments, exhibited similar enzyme characteristics to those observed for the QA sensitive NAALAD-ase activity. It has previously been shown that alignment of NAALAD-ase I with zinc amino peptidases from yeast and bacteria identifies a domain of conserved sequences involved in the co-ordination of two zinc ions located in the catalytic site (Bzedga et al., 1997), Rawlings et al., 1997). The basis for these observations comes from the three dimensional crystal structure of the *Aeromonas proteolytica* zinc aminopeptidase in which residues His 379, Asp 389, Glu 427, Asp 455, His 555 are thought to be involved in the binding of two zinc ions and Glu426 is proposed to be a base residue important in catalysis (Chevrier et al., 1994, 1996). Alignment of the newly identified NAALAD-ases with these amino peptidases (Fig. 8) shows that these zinc binding domains are conserved, suggesting that they may all share the same catalytic mechanism. Bzedga and colleagues (1997) have further suggested that NAALAD-ase I may be a member of the α/β hydrolase fold family because of its dipeptidyl IV and acylaminoacyl peptidase activity, although sequence homology alignments have shown these proteins to be clearly distinct. However, a hypothesised catalytic site arrangement of nucleophile, acid and base (Ser 623, Asp 663 and His 686) is covered and found in NAALAD-ase I, L and II but absent from NAALAD-ase IV (see Fig. 6). The second γ -linked enzymatic activity of NAALAD-ase I to peptides such as pteroyl- γ -glutamate (folate hydrolase activity) has been found at high levels in the brush border of human

small intestine (Chandler et al., 1986; Pinto et al., 1996). In addition, carcinoma cells transfected with NAALAD-ase I show increased folate hydrolase activity and the ability to progressively liberate glutamate from methotrexate triglutamate by hydrolysis of γ -glutamyl linkages (Pinto et al., 1996). Indeed, a correlation has been observed between increased pteroyl hydrolases activity and methotrexate resistance in tumours (Banerjee et al., 1986), suggesting that modulating NAALAD-ase activity may be important in developing improved or novel cancer treatments. It will be interesting to determine if these novel NAALAD-ase enzymes with their common secondary structure also have a dual peptidase activity as has been described NAALAD-ase I, and how their structural relationship reflects their activity. Using FISH analysis to determine the chromosomal localisation of NAALAD-ase I, II and L we observed a symmetrical fluorescent signal on chromosome 11, at p11.21 for NAALAD-ase I, q12 for NAALAD-ase L and between q14.3-q21 for NAALAD-ase II. In our FISH studies a NAALAD-ase I probe revealed two hybridisation signals, one hybridising at 11p11.21 and another weakly at 11q14.3. This is similar to the results obtained by Leek and colleagues (1995) who observed two hybridisation signals at 11p11.2 and 11q13.5. Having now localised NAALAD-ase II to 11q14.3-q21, it is clear that the second signal is due to cross hybridisation of the NAALAD-ase I probe with the NAALAD-ase II locus. The chromosomal localisation of NAALAD-ase IV revealed a symmetrical fluorescent signal on human chromosome 8 at q21.3, suggesting that this gene is distantly related to the other three genes located on chromosome 11. Chromosome 11 contains a number of genetic disease loci in these regions, including vitreoretinopathy (11q13-q23), xeroderma pigmentosa (11q12-q13), atopy (11q12-q13)

and perhaps more interestingly a tumour suppression locus (11p11.2-p11.13) involved in rat prostate carcinoma. Introduction of this portion of the chromosome into highly metastatic rat prostatic cells was able to suppress cancer metastases without suppression of the in vivo growth rate or tumourgenicity of the cells (Ichikawa et al., 1992). Since it has been shown that NAALAD-ase I expression increases with decreasing androgen levels, it is possible that current prostate cancer treatments involving androgen level reduction (e.g. orchidectomy) may work at least in part through alteration of NAALAD-ase expression (Israeli et al., 1994). The enzymatic activity of NAALAD-ase I is similar to that of NAALAD-ase II and L, so it is also conceivable by analogy that these enzymes may also have a role to play in tumour suppression. Interestingly, region 11q13-q23 has also been identified as a region with tumour suppressor activity using tumourgenic HeLa/fibroblast hybrids (Misra and Srivatsan, 1989). In addition, in a systematic analysis of primary cervical carcinomas, region 11q22-q24, was shown to contain tumour suppressor activity (Hampton et al., 1994). These latter two tumour suppressing regions on the long arm of chromosome 11, cover the gene loci of NAALAD-ase L and NAALAD-ase II identified in this study. However, it should be noted that mapping of these tumour suppressing activities to these three chromosomal regions, in no way establishes if any of the identified NAALAD-ases are capable of having tumour or metastatic suppressing activity. α -NAAG is one of the most abundant peptides in the brain, being present in millimolar concentrations in certain brain regions (see Coyle, 1997). Clarification of the physiological role of NAAG has been difficult as it is co-localised with L-glutamate, but it does fulfil some of the criteria for a neurotransmitter. It is

localised in synaptic vesicles; is realised in Ca^{2+} dependent manner from nerve terminals and is rapidly inactivated by a QA sensitive enzyme activity first identified in brain membrane preparations (Robinson et al., 1986, 1987). Cloning experiments revealed the sequence identity of this enzymatic activity to be derived from a previously identified protein, PSM (or NAALAD-ase I, Carter et al., 1996). In this study, NAALAD-ases I and II but not NAALAD-ase IV, have been shown to be able to hydrolyse $[3\text{H}]\text{-NAAG}$ to N-acetylaspartate and glutamate as has been previously shown with NAALAD-ase I. Given the localisation of these NAALAD-ases in prostate and ovary, as well as other peripheral tissues, it is quite possible that these enzymes may modulate local extracellular glutamate levels in these tissues. For example it is known that substantial amounts of glutamate are present in seminal fluid. In the CNS, NAAG has been shown to act as a partial agonist at the NMDA receptor but not at AMPA or kainate receptors (Vallivullah et al., 1994; Puttfarcken et al., 1993; Sekiguchi et al., 1992) and to attenuate NMDA or glutamate induced neurodegeneration (Bruno et al., 1998). Furthermore, it has also been shown that addition of NAAG to hippocampal slices or mixed cortical cultures results in neuroprotection following addition of excitotoxins via a mechanism distinct from its action of the NMDA receptor. In this case it is postulated that NAAG, which is poorly transported or actively taken up, diffuses from the synaptic cleft and binds as an agonist to type II metabotropic glutamate receptors (mGluR), such as mGluR3, leading to reduced glutamatergic neurotransmission (Wroblewska et al., 1993 and 1997). This hypothesis has been further tested using the mGluR3 antagonist, ethylglutamate, which eliminated the neuroprotective actions of NAAG (Bruno et al., 1998). Although the intact peptide has

predominantly inhibitory actions, another possible mechanism of excitotoxic induced cell death may arise from the aberrant catabolism of NAAG by NAALAD-ases. With endogenous levels of NAAG being so high in brain, catabolism of NAAG by NAALAD-ases should in theory be a rich source of glutamate, which if not properly regulated may result in excitotoxic effects. Indeed abnormal levels of NAAG or NAALAD-ase activity have been reported in epilepsy (Myerhoof et al., 1985 and 1992), Schizophrenia (Tsai et al., 1995), ALS (Tsai et al., 1991), Alzheimer's disease (Passani et al., 1997a; Jaarsma et al., 1994 and stroke (Sager et al., 1995). Inhibition of NAALAD-ase activities with specific inhibitors may be useful in treating ischemic induced neurodegeneration or other neurodegenerative disorders involving abnormalities in glutamate neurotransmission, such as Alzheimer's disease, schizophrenia or ALS (Passani et al., 1997b). In vitro at least, the NAALAD-ase (carboxypeptidase) inhibitor, 2-(phosphonemethyl) pentanedoic acid, inhibited toxicity induced by the carboxypeptidase cleavage of folic acid hexaglutamate (Slusher et al., 1997).

References.

- Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and
Lipman, D.J. (1990). Basic local alignment search
5 tool. J. Mol. Biol., 215, 403-410.
- Bruno, V., Wroblewska, B., Wroblewski, J.T., Fiore, L.
and Nicoletti, F. (1998) Neuroprotective activity of
n-acetylaspartylglutamate in cultured cortical cells.
10 Neurosci., 85(3), 751-757.
- Burlina, A.P., Skaper, S.D., Mazza, M.R., Ferrari, V.,
Leon, A. and Burlina, A.B. (1994) N-
acetylaspartylglutamate selectively inhibits neuronal
15 responses to N-methyl-D-aspartic acid in vitro. J.
Neurochem., 63(3), 1174-7, 1994.
- Bzdega, T., Turi, T., Wroblewska, B., She, D., Chung,
H.S., Kim, H. and Neale, J.H. (1997). Molecular
20 cloning of a peptidase against N-
acetylaspartylglutamate from a rat hippocampal cDNA
library. J. Neurochem., 69, 2270-2277.
- Carter, R.E. Feldman, A.R. and Coyle, J.T. (1996)
25 Prostate-specific membrane antigen is a hydrolase with
substrate and pharmacologic characteristics of a
neuropeptidase. P. Natl. Acad.Sci. USA., 93(2), 749-
753.
- Cassidy, M. and Neale, J.H. (1993) N -
30 acetylaspartylglutamate catabolism is achieved by an
enzyme on the cell surface of neurons and glia.
Neuropeptides., 25(4), 271-278.
- Chandler, C.J., Wange, T.T. and Halsted, C.H. (1996)
35 Pteroylpolyglutamate hydrolase from human jejunal
brush borders. Purification and characterisation.

J.Biol.Chem., 261(2), 928-933.

- 5 Chevrier, B., D'Orchymont, H., Schalk, C., Tarnus, C.
and Moras, D. (1996) The structure of the *Aeromonas*
proteolytica aminopeptidase complexed with a
hydroxamate inhibitor. Involvement in catalysis of
Glu51 and two zinc ions of the co-catalytic unit.
Eur.J. Biochem., 237(2), 393-398.
- 10 Chevrier, B., Schalk, C., D'Orchymont, H., Rondeau,
J.M., Moras, D. and Tarnus, C. (1994) Crystal
structure of the *Aeromonas proteolytica*
aminopeptidase, a prototypical member of the co-
catalytic zinc enzyme family. Structure, 2, 283-291.
- 15 Coyle, J.T. (1997) The nagging question of the
function of N-acetylaspartylglutamate. Neurobio.
Disease., 4(3-4), 231-238,
- 20 Ghose, S., Wroblewska, B., Corsi, L., Grayson, D.R.,
De Blas, A.L., Vicini, S. and Neale, J.H. (1997) N-
acetylaspartylglutamate stimulates metabotropic
glutamate receptor 3 to regulate expression of the
GABA(A) α_6 sub-unit in cerebellar granule cells. J.
- 25 Neurochem., 69(6), 2326-2335.
- 30 Hampton, G.M., Penny, L.A., Baergen, R.N., Larson, A.,
Brewer, C., Liao, S., Busby-Earle, R.M., Williams,
A.W., Steel, C.M., Bird C.C., Stanbridge, E.J. and
Evans, G.A. (1994) Loss of heterozygosity in sporadic
human breast carcinoma, a common region between 11q22
and 11q23.3. P. Natl. Acad.Sci. USA., 91 (6953-6957).
- 35 Ichikawa, T., Ichikawa, Y., Doing, J., Hawkins, A.L.,
Griffin, C.A., Isaacs, W.B., Oshimura, M., Barrett,
J.C. Isaacs, J.T. (1992) Localisation of metastasis
suppressor gene(s) for prostatic cancer to the short

arm of human chromosome 11. *Cancer Res.*, 52(12), 3486-3490.

- 5 Israel, R.S., Powell, C.T., Corr, J.G., Fair, W.R. and Heston, W.D. (1994) Expression of the prostate-specific membrane antigen. *Cancer Res.*, 54(7), 1807-1811.
- 10 Israeli, R.S., Powell, C.T., Fair, W.R. Heston, W.D. (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. *Cancer Res.*, 53(2), 227-230. *J. Neurochem.*, 69(1), 174-181.
- 15 Jaarsma, D., Veenma-van der Duin, L. and Korf, J. (1994) N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. *J. Neurol. Sci.*, 127(2), 230-233.
- 20 Kenny, A.J. and Maroux, S. (1982) Topology of microvillar membrane hydrolases of Kidney and intestine. *Physiol.Revs.* 62(1), 91-128.
- 25 Kozak, M. (1989) The scanning model for translation, an update. *J. Cell Biol.*, 108, 229-241.
- Kyte, J and Doolittle, R.F. (1982) A simple method for displaying the hydropathic character of a protein. *J. Mol. Biol.*, 157(1), 105-132.
- 30 Leek, J., Lench, N., Maraj, B., Baily, A., Carr, I.M., Andersen, S., Cross, J., Whelan, P., MacLennan, K.A., Meredith, D.M. and Markham, A.F. (1995) Prostate-specific membrane antigen, evidence for the existence of a second related human gene. *Brit. J. Cancer*,
- 35 72(3), 583-588.
- Luthi-Carter, R., Berger, U.V., Barczak, A., Enna, J.

- Coyle, J.T. (1998) Isolation and expression of a rat brain Cdna encoding glutamate carboxypeptidase II. P. Natl. Acad.Sci. USA., 95(6), 3215-3220.
- 5 Meyerhoff, J.L., Carter, R.E., Yourick, D.L., Slusher, B.S. and Coyle, J.T. (1992) Activity of a NAAG-hydrolyzing enzyme in brain may affect seizure susceptibility in genetically epilepsy-prone rates. Epilepsy Research (Supp.), 9, 163-172.
- 10 Meyerhoff, J.L., Robinson, M.B., Bixler, M.A., Richards, S.S. and Coyle, J.T. (1989) Seizures decrease regional enzymatic hydrolysis of N-acetylaspartylglutamate in rat brain. Brain Res., 505(1), 130-134.
- 15 Meyerhoff, J.L., Koller, K.J., Walczak, D.D. and Coyle, J.T., (1985) Regional brain levels of N-acetylaspartyl-glutamate, the effect of kindled seizures. Brain Res., 346(2), 392-396.
- 20 Misra, B.C. and Srivatsa, E.S. (1989) Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome 11. Am. J. Hum. Genet., 45(4), 565-577.
- 25 Orlando, L.R., Luthi-Carter, R., Standaert, D.G., Coyle, J.T., Penney, J.B Jr. and Young, A.B. (1997) N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci. Letts., 236(2), 91-94.
- 30 Passani, L.A., Vonsattel, J.P. and Coyle, J.T. (1997) Distribution of N-acetylaspartyl-glutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res., 772(1-2), 9-22.
- 35

- Passani, L.A., Vonsattel, J.P., Carter, R.E. and Coyle, J.T. (1997) N-acetylaspartyl-glutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in
5 Huntington and Alzheimer's diseases. Mol. Chem. Neuropathol., 31(2), 97-118.
- Pinto, J.T., Suffoletto, B.P., Berzin, T.M., Qiao, C.H., Lin, S., Tong, P.T., May, F., Mukherjee, B. and
10 Heston, W.D. (1996) Prostate-specific membrane antigen, A novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 2, 1445-1451.
- Puttfarcken, P.S., Handen, J.S., Montgomery, D.T.,
15 Coyle, J.T. and Werling, L.. (1993) N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [3H] norepinephrine release from rat hippocampal slices. J. Pharmacol. Exp. Ther., 266(2), 796-803.
- 20 Rawlings, N.D. and Barrett, A.J. (1997) Structure of membrane glutamate carboxypeptidase. Biochim. et Bioph. Acta., 1339(2), 247-252.
- 25 Robinson, M.B., Blakely, R.D., Couto, R. and Coyle, J.T. (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterisation of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol.
30 Chem., 262(30), 14498-14506.
- Robinson, M.B., Blakely, R.D. and Coyle, J.T. (1986) Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate in
35 vitro. Eur. J. Biochem., 130(3), 345-347.
- Sager, T.N., Laursen, H. and Hansen, A.J. (1995)

Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat. *J. Cerebr. Blood F. Met.*, 15(4), 639-646.

- 5 Sekiguchi, M., Wada, K. and Wenthold, R.J. (1992) N-acetylaspartylglutamate acts as an agonist upon homomeric NMDA receptor (NMDAR1) expressed in *Xenopus* oocytes. *FEBS Letts.*, 311(3) 285-289.
- 10 Serval, V., Barbeito, L., Pittaluga, A., Cheramy, A., Lavielle, S. and Glowinski, J. (1990) Competitive inhibition of N-acetylated- α -linked acidic dipeptidase activity by N-acetyl-L-aspartyl- β -linked L-glutamate. *J. Neurochem.*, 55(1), 39-46.
- 15 Shneider, B.L., Thevananther, S., Moyer, M.S., Walters, H.C., Rinaldo, P., Deverajan, P., Sun, A.Q., Dawson, P.A. and Ananthanarayanan M. (1997) cloning and characterisation of a novel peptidase from rat and
- 20 human ileum. *J. Biol. Chem.*, 272(49), 31006-31015.
- Slusher, S., Thomas A.T., Jackson, P.F., Tiffany, C.W. and Suzdak, P.D. (1997) Folate polyglutamate toxicity in rat cortical neurones is attenuated by NAALAD-ase
- 25 inhibition. *Soc. Neurosci. Abst.*, 898.7.
- Su, S.L., Huang, I.P., Fair, W.R., Powell, C.T. and Heston, W.D. (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA, ratio of
- 30 expression as a potential measurement of progression. *Cancer Res.*, 55(7), 1441-1443.
- Tsai, G., Passani, L.A., Slusher, B.S., Carter, R., Baer, L., Kleinman, J.E. and Coyle, J.T. (1995)
- 35 Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. *Arch. Gen. Psych.*, 52(10), 829-836.

- 5 Tsai, G.C., Stach-Slusher, B., Sim, L., Hedreen, J.C.,
Rothstein, J.D., Kuncl, R. and Coyle, J.T. (1991)
Reductions in acidic amino acids and N-
acetylaspartylglutamate in amyotrophic lateral
sclerosis CNS. Brain Res., 556(1), 151-156.
- 10 Valivullah, H.M., Lancaster, J., Sweetnam, P.M. and
Neale, J.H. (1994) Interactions between N-
acetylaspartylglutamate and AMPA, kainate, and NMDA
binding sites. J. Neurochem., 63(5), 1714-1719.
- 15 Wroblewska B., Wroblewski JT., Saab OH., Neale JH.
(1993) N-acetylaspartylglutamate inhibits forskolin-
stimulated cyclic AMP levels via a metabotropic
glutamate receptor in cultured cerebellar granule
cells. J. Neurochem., 63(3), 943-948.
- 20 Wroblewska, B., Wroblewski, J.T., Pshenichkin, S.,
Surin, A., Sullivan, S.E. and Neale, J.H. (1997) N-
acetylaspartylglutamate selectively activates mGluR3
receptors in transfected cells. J Neurochem., 69, 174-
181.

25

30

Table 1:

	NALAAD-I	NALAAD-L	NALAAD-II	NALAAD-IV
NAALAD-I	100	54	81	21
NAALAD-L	35	100	54	17
NAALAD-II	67	37	100	21
NAALAD-IV	10	9	11	100

Comparison of the predicted protein sequences for
NAALAD-ase I, L, II and IV. The sequences were
compared two by two using the alignment program
BESTFIT (GCG package). The obtained values for %
IDENTITY (upper part of the table) and % similarly
(lower part of the table) are shown.

15

List of used abbreviations.

	BLAST	basic local alignment search tool
	bp	base pairs
5	CMV	cytomegalovirus
	DMEM	defined minimal essential medium
	EST	expressed sequence tag
	FISH	fluorescent in situ hybridisation
	GAPDH	glyceraldehyde-3-phosphate
10		dehydrogenase
	I100	ileal 100 kDa protein
	IPTG	isopropyl- β -D-thiogalactoside
	MEM	minimal essential medium
	NAALAD-ase	N-acetylated alpha-linked acidic
15		dipeptidase
	NAAG	N-acetyl-L-aspartyl-L-(3,4)-glutamate
	ORF	open reading frame
	PBS	phosphate buffered saline
	PCR	polymerase chain reaction
20	PSM	prostate specific marker
	QA	quisqualate
	RACE	rapid amplification of cDNA ends
	RT-PCR	reverse transactiption polymerase chain
		reaction
25	SDM	site directed mutagenesis
	SPA	scintillation proximity assay
	SSC	sodium chloride sodium citrate
	TAE	Tris acetate EDTA
	X-Gal	5-bromo-4-chloro-3-indolyl-B-D-
30		galactopyranoside

Claims

1. A cDNA molecule encoding a human NAALAD-ase L protein having the amino acid sequence illustrated in figure 1 or a functional equivalent, derivative or bioprecursor thereof.
5
2. A cDNA molecule according to claim 1 which cDNA comprises the sequence of nucleotides illustrated in Figure 1.
10
3. A cDNA molecule encoding any of the splice variants of human NAALAD-ase L proteins having the amino acid sequences illustrated in Figure 3.
15
4. A cDNA molecule according to claim 3 which DNA molecule comprises the sequence of nucleotides illustrated in Figure 1 having respective nucleotide deletions or insertions encoding the respective splice variants of human NAALAD-ase L illustrated in Figure 3.
20
5. A cDNA molecule encoding a NAALAD-ase II protein having the amino acid sequence illustrated in Figure 4 or a functional equivalent, derivative or bioprecursor thereof.
25
6. A cDNA molecule according to claim 5 which cDNA molecule comprises the nucleotide sequence illustrated in Figure 4.
30
7. A cDNA molecule encoding a NAALAD-ase IV protein having the amino acid sequence illustrated in Figure 5 or a functional equivalent, derivative or bioprecursor thereof.
35
8. A cDNA molecule according to claim 7 having

the nucleotide sequence illustrated in Figure 5.

5 9. A nucleic acid molecule capable of
hybridising to the cDNA molecules according to any of
claims 1 and 8 under high stringency conditions.

10 10. A human NAALAD-ase L protein having an amino
acid sequence encoded by the nucleotide sequence
illustrated in Figure 1 or a functional equivalent or
derivative thereof.

15 11. A human NAALAD-ase L protein according to
claim 10 having the amino acid sequence illustrated in
Figure 1 or including the insertions or deletions of
the amino acid sequence illustrated in Figure 3.

20 12. A NAALAD-ase II protein or a functional
equivalent, derivative or bioprecursor thereof,
encoded by the nucleotide sequence illustrated in
Figure 4.

13. A protein according to claim 12 which is a
human NAALAD-ase II protein.

25 14. A protein according to claim 12 or 13 having
the amino acid sequence illustrated in Figure 4.

30 15. A NAALAD-ase IV protein or a functional
equivalent, derivative or bioprecursor thereof, having
an amino acid sequence encoded by the nucleotide
sequence illustrated in Figure 5.

35 16. A protein according to claim 15 which is a
human NAALAD-ase IV protein.

17. A protein according to claim 15 or 16 having
the amino acid sequence illustrated in Figure 5.

- 66 -

18. A DNA expression vector which comprises a cDNA molecule according to any of claims 1 to 8.

5 19. A vector according to claim 18 which vector comprises a cytomegalovirus promoter.

20. A vector according to claim 18 or 19 which comprises a sequence encoding a reporter molecule.

10 21. A host cell transformed or transfected with the vector according to any of claims 18 to 20.

22. A host cell according to claim 21 which cell comprises a prokaryotic or eukaryotic cell.

15 23. A host cell according to claim 21 or 22 which is a COS cell.

20 24. A transgenic cell, tissue or organism comprising a transgene capable of expressing a protein according to any of claims 10 to 17.

25 25. A transgenic cell, tissue or organism according to claim 24 wherein said transgene comprises a vector according to any of claims 18 to 20.

26. A cDNA or nucleic acid molecule according to any of claims 1 to 9, or a functional equivalent thereof, for use as a medicament.

30 27. Use of a cDNA or nucleic acid molecule according to any of claims 1 to 9, or a functional fragment thereof, in the preparation of a medicament in the treatment of neural diseases including
35 Alzheimer's disease, schizophrenia, ALS, Parkinsons disease, peripheral neuropathy, Huntingdon's disease, acute brain injury, multiple sclerosis, exposure to

neurotoxins, peripheral nerve trauma, ischaemia or dementia.

28. A pharmaceutical composition comprising a
5 nucleic acid or cDNA molecule according to any of
claims 1 to 8 or a protein according to any of claims
10 to 17 together with a pharmaceutically acceptable
carrier, diluent or excipient therefor.

10 29. A method of determining whether a compound is
an inhibitor or an enhancer of activity of a NAALAD-
ase protein according to any of claims 10 to 17 which
method comprises contacting said compound with NAALAD-
ase protein in the presence of [³ H] N-acetyl-L-
15 aspartyl-L-glutamate (NAAG), and monitoring for the
extent of hydrolysis NAAG compared to a control of
said NAALAD-ase and NAAG which is not contacted with
said compound.

20 30. A compound identifiable as an inhibitor or
enhancer of NAALAD-ase activity according to claim 29.

31. A compound according to claim 30 for use as a
medicament.

25

32. Use of a compound according to claim 30 in
the preparation of a medicament for the treatment of
neural diseases or disorders such as Alzheimer's
disease, schizophrenia, ALS, Parkinsons disease,
30 peripheral neuropathy, Huntingdon's disease, acute
brain injury, multiple sclerosis, exposure to
neurotoxins, peripheral nerve trauma, ischaemia or
dementia.

35 33. A pharmaceutical composition comprising a
compound according to claim 30 together with a
pharmaceutically acceptable carrier, diluent or

excipient therefor.

34. A method of identifying a compound which is an inhibitor or an enhancer of expression or activity of a NAALAD-ase protein according to any of claims 10 to 17 which method comprises contacting a host cell, tissue or organism expressing said protein with a compound to be tested and monitoring the expression or activity of said protein compared to a control which comprises said cell expressing said protein but which has not been contacted with said compound.

35. A method according to claim 34 wherein said NAALAD-ase expressing cell comprises a host cell according to any of claims 21 to 23 or a transgenic cell, tissue or organism according to claims 24 or 25.

36. A method according to claim 35 wherein said monitoring step comprises monitoring for the expression of said reporter molecule.

37. A compound identifiable as an inhibitor or an enhancer of expression or activity according to the methods of any of claims 34 to 36.

25

38. A compound according to claim 37 for use as a medicament.

39. Use of a compound according to claim 37 in the preparation of a medicament for treating neural disorders such as Alzheimers's disease, schizophrenia, ALS, Parkinsons disease, peripheral neuropathy, Huntingdon's disease, acute brain injury, multiple sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or dementia.

35

40. A pharmaceutical composition comprising a

- 69 -

compound according to claim 37 together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

5 41. A method of quantifying enzyme activity which method comprises

 (a) contacting an enzyme of interest with a radiolabelled hydrolysable substrate thereof in the
10 presence of SPA beads;

 (b) stopping said reaction by adding glycine buffer; and

15 (c) monitoring the signal from said substrate bound to said beads.

 42. A method of identifying a compound which is an inhibitor or an enhancer of activity of an enzyme,
20 said method comprising;

 (a) contacting an enzyme of interest with a radiolabelled hydrolysable substrate thereof
 in the presence of SPA beads and said
25 compound to be tested;

 (b) stopping said reaction by adding glycine buffer;

30 (c) monitoring the signal from the substrate bound to said beads compared to a control which has not been contacted with said compound.

35 43. A method according to claim 41 or 42 wherein said substrate comprises [³H] NAAG and said enzyme comprises a NAALAD-ase enzyme.

- 70 -

44. A method according to any of claims 41 to 43 wherein said enzyme comprises a NAALAD-ase according to any of claims 10 to 17.

5 45. A compound identifiable as an inhibitor or an enhancer of NAALAD-ase activity according to the method of claims 43 or 44.

10 46. A pharmaceutical composition comprising a compound according to claim 45, together with a pharmaceutically acceptable carrier, diluent or excipient thereof.

15 47. A compound according to claim 45 for use as a medicament.

20 48. Use of a compound according to claim 45 in the manufacture of a medicament for treating neural disorders such as Alzheimers's disease, schizophrenia, ALS, Parkinsons disease, peripheral neuropathy, Huntingdon's disease, acute brain injury, multiple sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or dementia.

FIG. 1

90 GCCAAGAGTCGCGCAGGATCGAGTGGACGAAGGTGTGGGGCTGGGGCTGCTGCCCTCTTGGGGCTGGGGATCATCTCGGCCA
M Q W T K V L G L G L G A A A L L G L G I L G H

180 CTTGCCATCCCCAAAAGCCAACTCACTGGCCCCCAGGACCTGGACCTGGAGATCTCGAGACCGTCAATGGGGCAGCTGGATGCCCA
F A I P K A N S L A P Q D L D L E I L E T V M G Q L D A H

270 CAGGATCGGGAGAACCTCAGAGAATCTCCAGGGAGCCACACCTGGCCCTCCAGCCCTCGGGATGAGCACCTGGTGCAGCTGCTCGCA
R I R E N L R E L S R E P H L A S S P R D E L V Q L L L Q

360 GCGCTGGAAGGACCCAGAGTCAGGCTGGACTCGGCCGAGGCCCTNCACGTACGAAGTGTGCTGTCTTCCCTAGCCAGGAGCAGCCCAA
R W K D P E S G L D S A E A X T Y E V L L S F P S Q E Q P N

450 CGTGTGGACATCGTGGGCCCCACTGGGGGCATCATCCACTCTGCCACCGGACTGAGGAGAACGTGACCGGGAGCAAGGGGGCCAGA
V V D I V G P T G G I I H S C H R T E E V T G E Q G G P D

540 TGTGGTACAACCCCTATGCTCTCTTCTGTGAACCCACAGGGCCCTCTGCTGTATGCCAACCCGGGGCGGGAAGACTTTAA
V V Q P Y A A Y A P S G T P Q G L L V Y A N R G A E E D F K

630 GGAGCTACAGACTCAGGGCATCAAACCTGAAGCACCATTCCTGACTGATATGGGGGTGTAGGGCGTGGGGCCAAAGCTGTGAACGC
E L Q T Q G I K L E G T I A L T R Y G G V G R G A K A V N A

720 TGCCAAGCACGGGGTAGCTGGGGTGTGTACACAGACCCCTGCCGACATCAACGATGGGCTGAGCTACCCGACGAAACCTTTCCCAA
A K H G V A G V L V Y T D P A D I N D G L S S P D E T F P N

810 CTCTGTGTACCTGCCCCCTCAGGAGTGGAGCGAGGCTCCTACTACGAGTATTTTGGGGACCCCTGTGACTCCCTACCTTCCAGCGGTCCC
S W Y L P P S G V E R G S Y Y E Y F G D P L T P Y L P A V P

900 CTCTTCTTCCGGCTGGACCTTGCCAAATGTCCTCCGGATTTCGCCCAATTCCTACAGCCCATTTGGCTTCCAGGATGCAAGAGACCTGCT
S S F R V D L A V S G F P P I P T Q P I G F Q D A R D L L

990 CTCTAACCTCAACGGAACCTTTGGCCCCCAGCCACCTGGCAGGGAGCACCTGGGCTGCCACTACAGTTGGGTCCCGGCTTCCGGCCTGACGG
C N L G T L A P A T W Q G A L G C H Y R L G P G F R P D G

1080 AGACTTCCAGCAGACAGCCAGGTGAATGTAGCGTCTACAAACCGCTGAGAGTGAAGAACTTTCACACGTCCTGGGCATCATCCGTGG
D F P A D S Q V V S V Y N R L E L R S S N V L G I I R G

1170 GGCTGTGGAGCCCTGATCGCTACGTGTATGGGAACCAACCGAGACAGCTGGGTGACCGGGCTGTGGACCCAGCAGTGGCACCCCGCT
A V E P D R Y V L Y G N H R D S W V H G A V D P S S G T A V

FIG. 1 (CONTINUED)

1260 CCTCTGAGCTCTCCCGTCTCTGGGACCTCTGTAAGAAGGACCTGGCGTCTTCGAGATCAATCGTGTTCGGAGCTGGGGGC
L L E L S R V L G T L L K K G T W R P R S I V F A S W G A

1350 TGAGGAGTTTGGGCTCAITGGCTCCACGGAATTCACAGAAGAGTTCCTCAACAAGCTGCAGGAGCGCACGGTGGCTTACATCAACGTGGA
E E F G L I G S T E F T E E F F N K L Q E R T V A Y I N V D

1440 CATCTCGGTGTTGCCAACGCTACCCCTTAGGGTGCAAGGAGCGCCCTCTGCAAGAGCGTCTCTCTGCAACCAAGAGATCCGCTC
I S V F A A T L R V Q G T P P V Q S V V F S A T K E I R S

1530 ACCAGGCCCTGGGACCTGAGCATCTACGAACCTGGATCCGGTACTTCAACCGCAGCAGCCGGTGTACGGCTGTGTCGCCAGCTTGGG
P G P G D L S I Y D N W I R Y F R S S P V Y G L V P S L G

1620 TTCTCTGGGTCTGGCAGGCACTATGCACCCCTTCGTTTCATCTTCTGGGATCTCTCCATGGACATTCCTTACCTATACCTATGACCGGAGCAA
S L G A G S D Y A P F V H F L G I S S M D I A Y T Y D R S K

1710 GACTTCAGCCAGGATCTACCCCACTACACACAGCCTTTGACACCTTTGACATATGTGACAAAGTTTTCGACCCGGCTTCAGCAGCCA
T S A R I Y P T Y H T A F D T F D Y V D K F L D P G F S S H

1800 TCAGGCTGTGGCCCGGACAGCGGAGTGTGATTTCTCCGGCTCAGTGACAGCTTCTTCTGCCCCCTCAAAGTCAGTACGTAGAGAC
Q A V A R T A G S V I L R L S D S F F L P L K V S D Y S E T

1890 ACTCCGAGCTTCTGTCAGGACGCCAGCAAGATCTTGGGGCCCTGCTGGAGCAGCAGCATCAGCCTGGGGCCCTTGGTACTGCAGT
L R S F L Q A A Q Q D L G A L L E Q H S I S L G P L V T A V

1980 GGAGAAGTTTGAGCAGAAGCTCCAGCCTTGGGCCCAAGCATATCAACACTGCAGAAGGCGAGCCTGACCCCTGCGAGGTCCGGATGCT
E K F E A E A A L G Q R I S T L Q K G S P D P L Q V R M L

2070 CAATGACCAGTTGATGCTCTTGAACGGACCTTCTGAACCCCTAGAGCCTTCCAGAGGAACGCTACTACAGCCATCTGCTCTGGGCACC
N D Q L M L L E R T F L N P R A F P E E R Y Y S H V L W A P

2160 TTCCGACCGGCTCCGTAGTCACATTCGCGGGCTATCCAAATGCTCTCCAGGGCCAGGACACAGCTTCTGGATCTGAAGCTTGGGCTGA
S H G L R S H I P G L S N A C S R A R D T A S G S E A W A E

2250 GGTCCAGAGACAGCTCAGCATTTGGTGACAGCCCTCGAGGGTGGGAGCCACCTGAGGCCCTGTGGTGAACCTCTGACCCGAGCCCTC
V Q R Q L S I V V T A L E G A A A T L R P V A D L .

2320 TTCTTCAGCCCTCCCTTTACTCCGGTGTATTATTTACAAGTGCTTTGTGTGTTTTTAAAGTCTTTT

FIG. 2.

human	MQMTKVLGLGLGAAALIGLGIILGHFAIPKANSAP-----QDLDELLETVMGQOLDARIRENLRISREPHLASPRDELVQLLIQ : 85
rat	HHAKILGVGIGAGAAALIGLGIILGHFAIPHATEPLSSVSQDLDLAILDSVHGQOLDASRIRENLRISKEPHVATSRDEALVQLLIG : 90
human	RUKDPESGLDSEAXTTEVLLSFPSQEQPIVVDIVGFTGGIHSCHRTEENVGTGCGPDVWQPYAAVAPSSTPQELVYANRCAEEDFH : 175
rat	RUKDSASGLDTAKTYETVLLSFPSQEQPNSVETVGENETVHFSFQPFENLTGCEAFENVLQPYAAVAFPGTFKGPLVYANRCSDDFH : 180
human	ELCTQGIKLEGTIALTRYGGVGRGAKAVTAAKHGVALSVLVYTDFAINDGLESPDETTPNSMVLPPSGVERGSYVEVFGDPLTPYLPAPF : 265
rat	KLEAEGINLKGTTIALTRYGSVGRGAKAIAARHGVALSVLVYTDGCDINDGKSLPNETTPNSMGLPPSGVERGSYVEVFGDPLTPYLPAPF : 270
human	SSFRVDLNVSGFPPIPTQPIGFQDARDLLCHLNGTLAPATUQGALGCCHYRLGPGHFPDGDFFADSQNVSVVNRLELRNSSNVLGILIG : 355
rat	VSFRLDPRHISGFPIPTQPIGFEDAKVLLCHLNGTSPADSMQGALGCCYKLGPGHFEENGFPAGSEVKVSVVNRLELRNSSNVLGILIG : 360
human	AVEPDRVLYGNHRDSUVHGAVDPSSTAVLLLSRVLGTLLKKGTURPRRSIVFASMGAEFGLIGSTEFTEEFNKLQERTVATINVD : 445
rat	AVEPDRTVIYGNHRDSUVHGAVDPSSTAVLLLSRVLGTLLKKGTURPRRSIIIFASMGAEFGLIGSTEFTEEFNKLQERTVATINVD : 450

FIG. 2. (CONTINUED)

human	ISVFATATLPVQGTTPVQSVVFSATKEIRSPGPGCLSIYDNMIRYEMRSSPVYGLVPSLGSGLGAGSDYAPFVHFLGISSINDIAYTYDRSH : 535
rat	ISVFSEATLFAQGTTPVQSVVFSATKEISAPGSSGCLSIYDNMIRYEMRSSPVYGLVPSLGSGLGAGSDYASFIFHFLGITSHDLAYTYDRSH : 540
human	TSARIPTYHTAFDTFDYVDFHLDPGFSSHQAVARTAGSVLLRLSDSFFFLPLRVSDYSETLRSFLQAAQODLGALLECHSISLGPLVTAV : 625
rat	TSARIPTYHTAFDTFDYVENKLDPGFSSHQAVARTAGSVLLRLSDSLFLPLNVSDYSETLQSFLLQAAQENLGALLESHNISLGPLVTAV : 630
human	ENFEAEAAALCGRTSTLQKSPDPLOVRHNDQHLLEFFFLNPRAPFPEERYSHVLWAPSHGLRSHIPGLSNACSRARDTASGEAAAE : 715
rat	ENFEAEAAALNCHLILQKSSPDPLOVRHNDQHLLEFFFLNPRAPFPEERYSHVLWAPNTASVATFPGLANAYARAQENINSGAEAAAE : 720
human	VQRQLSIWVTALEGAATLCPVADL-- : 740
rat	VQRQLSIWVTALEGAATLCPVTDL-- : 745

MQ'WTKVLGLGAAALLGLGIILGHFAIPKKANSLAPOQLDLEILETVMGQLDAHRIRENLRSLASSPRDEDLVQLLQRWKDP 90

deletion 1 (bp 497-619)

ESGLDSAEAXTYEVLSPSPSQEQPNVWDIVGPTGGIIHSCRTEENVGTGEQGGPDVVQPYAAVAPSGTPQGLLVYANRGAEEEDFKELQTQ 180

GIKLEGTIALTRYGGVGRGAKAVNAAKHGVAGLVVYTDPADINDGLSSPDETFPNSWYLPSPGVERGSYYEYFGDPLTPYLPAPVSSFRV 270

gtgagcgtctacaaccgctggagctgaggaactcttcaacgtcctgggcacatcag
ctggggctgtggagcctggtgagccctctctgtcctgcacccagccctgtctct
gctctgagtgcgctgctctatccagcctgacctgcacacccagccagctccc
cctgccacactctcctctctctctgttctctctgcccctttctctctggccag

deletion 2 (bp 903-1007)

insertion at bp 1094

DLANVSGFPPIPTQPIGQDARDLLCNLNGTLAPATWOGALGCHYRLGPGFRPDGDFPADSQVNVSVYNRLELRNSSNVLGIIRGAVEP- 359



-----DRVLYGNHRDSWVHGAVDPSSGTAVLLELSRVLTLLKK 399

EPSSCCLHPRPLCSGCRCPHALPLPPSPAPPAHLSSLSSGSLPLFLNP

GTWRPRRSIVFASWGAEEFGLIGSTEFTEEFFNKLQERTVAYINVDISVFANATLRVQCTPPVQSVFVSATKEIRSPGPGDLSIYDNWIR 489

FIG. 3. (CONTINUED)




FIG. 4.

90 CTCAAGAAGCCATGGCGGAATCCAGGGCGCTGTGTACCTTTGGATGTGCTGGCTGGCTGGCATCTTCTCATGGGATTTATGG
 M A E S R G R L Y L W M C L A A A L A S F L M G F M V
 180 TGGGCTGGTTTATTAAAGCCTCTCAAAGAAACAACCACTTCTGTGGCGCTATCATCAAGTATACGGTGAACATGGTATCCGAATGAAAG
 G W F I K P L K E T T S V R Y H Q S I R W K L V S E M K A
 270 CTGAACAATCAATTTCTTCTTCTTTTACAAAGCTTCTCATCTGGCAGGAACAGAAACAAAATTTCTGTGCTGCCAAGAAATCC
 E N I K S F L R S F T K L P H L A G T E Q N F L L A K K I Q
 360 AAACCCAGTGGAGAAATTTGGACTAGATTTCAGCCCAAGTTGGTTTCAATTATGATGCTCTTATCTTACCCCAATGAGACAAATGCCAACT
 T Q W K K F G L D S A K L V H Y D V L L S Y P E T N A N Y
 450 ATATATCGATTGTGGATGAACATGAAGATTTTCAAAACATCATACCTTGAACCAACCAGATGCTATCAGAAATGTTACAATA
 I S I V D E H E T E I F K T S Y L E P P D G Y E V T N I
 540 TTGTGCCACCATATAATGCTTTCTCAGCCCAAGCATGCCAGAGGAGATCTTGTAATGTGAACATATGCTCGCACTGAAGACTTTTCA
 V P P Y N A F S A Q G M P E G D L V Y V N Y A R T E D F F K
 630 AACTAGAAAGAGATGGGCATCACTGTACTGGGAAGATGTTATTGCAAGATATGGAATAATCTTCAGAGGAAATAAGTTAAATG
 L E R E M G I C T G K I V I A R Y G K I F R G N K V K N A
 720 CCATGTTAGCAGGAGCCATAGGAATCATCTTGTACTCAGATCCAGCTGACTACTTTGCTCTCAGGTACAGCCATATCCCAAGGATGGA
 M L A G A I G I I L Y S D P A D Y F A P E V Q P Y P K G W N
 810 ATCTTCTGGAACCTGCAGCCAGAGAGAAATGTGTTAAATTTGAATGGTGTGACCCACTCACTCCAGGCTATCCAGCAAAAGAAAT
 L P G T A A Q R G N V L N L N G A G D P L T P G Y P A K E Y
 900 ACACCTTCAGACTTGATGTTGAAGAGGAGTGGGAATCCCCCGAATACCTGTACATCCCATGGATAAATGATGCAAAATATTATAC
 T F R L D V E E G V G I P R I P V H P I G Y N D A E I L L R
 990 GCTACTTGGAGGAATGCTCCACCAGATAAGAGTTGGAAGGGAGCCCTTAATGTGAGTTATAGTATCGGACCTGGCTTTACAGGGAGTG
 Y L G G I A P P D K S W K G A L V S Y S I G P G F T G S D
 1080 ATTCTTTCAAGGAAGTTAGAAATGATGTTTATAACATCAATAAATTACAGGATTTACAAATGTAGTTGGAACATATCAGAGGATCTGTGG
 S F R K V R M H V Y N I N K I T R I Y N V V G T I R G S V E
 1170 AACCTGACAGGTATGTTATCTGGAGGTACCGGGACTCTCGGTATTGAGCTATTGACCCCAACCACTGGGGTGTCTGTTTGCAG
 P D R Y V I L G G H R D S W V F G A I D P T S G V A V L Q E

FIG. 4. (CONTINUED 1)

1260 AAATTGCCCGGAGTTTGGAAAACTGATGAGTAAAGGCTGGAGACCTAGAAGACTATCATTTTCCAGCTGGATGCAAGAAATTG
 I A R S F G K L M S K G W R P R R T I I F A S W D A E E F G
 1350 GACTTCTGGGTTCCACAGAAATGGCTGAGGAGAAATGTCAAAAATCTCCAGGAGAGAGCATGCTTATATCAACTCGGATTCTATAG
 L L G S T E W A E E N V K I L Q E R S I A Y I N S D S S I E
 1440 AAGGCAATTATACTCTCAGAGTTGACTGTACTCCCTCTTTTACCAATTAGTGATAACTGACAAAAGAGATCCCCAGCCCTGATGATG
 G **[N]** Y T L R V D C T P L L Y Q L V Y K L T K E I P S P D D G
 1530 GGTTCAGAGTAAATCACTGTATGAAGCTGGTTGGAAAAAGACCCCTTCACCTGAAATAAAAAATTTGGCTAGATCAATAAGCTGGAT
 F E S K S L Y E S W L E K D P S P E N K N L P R I N K L G S
 1620 CTGGAAGTGACTTTGAAGCTTATTTTCAGAGACTTTGGAAATGCTTCAGGCAGAGCCGTTACACTAAGATATAGAAAACAGATAAGTACA
 G S D F E A Y F Q R L G I A S G R A R Y T K N K K T D K Y S
 1710 GCAGTACCCAGTGTAACACACAATTTATGAGACATTTGAAATTTGATGAGAGAAATTTATGACCCACATTTTAAAAAACAACCTTTCTGTGG
 S Y P V Y H T I Y E T F E L V E K F Y D P T F K K Q L S V A
 1800 CTCATTTACGAGGAGCACTGGTATATGAGCTTTGGATTCTTAAATCATTCCTTTTAAATATTCAAAGACTATGCAGAAGCTTTTGAAAAACT
 Q L R G A L V Y E L V D S K I I P F N I Q D Y A E A L K N Y
 1890 ATGCAGCAAGTATCTATATCTAAGAAACATGATCAACAAATTAACAGACCAATGGAGTATCATTTGACTCCTTATTTCTGCTGTGA
 A A S I Y **[N]** L S K K H D Q Q L T D H G V S F D S L F S A V K
 1980 AAACTTCTCAGAGGCTGCTTCAGATTTTTCATAAACGACTTATCAAGTTGATCTTAAACAATCCCAATTCAGTGCAGATGATGAATGACC
[N] F S E A A S D F H K R L I Q V D L N N P I A V R M N D Q
 2070 AACTGATGCTCTGGAAGAGCATTCATCGATCCTCTTGGTTTACAGGAAAGCTGTCTTATAGGCACATCATATTTGCTCCAAGTAGCC
 L M L L E R A F I D P L G L P G K L F Y R H I I F A P S S H
 2160 ACAACAAATATGCTGGAGAAATCATTTCTGGAATCTATGATGCTATCTTTTGATATTGAAAATAAAGCCAACTCTCGTTTGGCCCTGGAAAG
 N K Y A G E S F P G I Y D A I F D I E N K A N S R L A W K E
 2250 AAGTAAAGAAACATATTTCTATGACGCTTTTACAAATTCAGCAGCAGCAGCACTCTGAAAGAAGTATTATAGAAAGTCTCAAGTGGCT
 V K K H I S I A A F T I Q A A A G T L K E V L .

FIG. 4. (CONTINUED 2)

AGCCATTAAAGGTGTGCTAAAGCTGAGGATAAAATTCACCTTTCTGTATAACTTAGAAGCCAGGGTGTTCATAAAGCTTTTTCATGTC 2340
ATGTTTTGATTATAGGCTTTGGTCTTTTCATCTGCAAAAGCCTTTTTTTTTTTGTCTCTTTTAAAGTTAATAATTATATTAGCAAAAGTGT 2430
AATCTAATGAAGTAAAAAACTCTCTGTGTGGCAGAAAGTAAAGAAAAATCCCTAAATTTATAGCAAGGAACATGAATTTCTCAGACATTGTG 2520
AGTGTGGGAATGTAAAAATGGTAAAAATCCTTTTGAAAAACAGTTTGGCAGTTTCCCTATAAAGTTAAACATACACTTTTACTTTAGGACTCC 2610
AGAAATCCACTTCTAGTTATTTATTTCAAGAGAGAGGAAAAACAATGATCACAGCAATACTTGTATGTCATGTTCAATTGCAACTTAAAAAGCGT 2700
AAAAACCCCAAAATGTCATCCACAGACGAAATGTATAAACTGTGGTATCCATTACACAAATAGACTACTTACTACTCAGCAATAAAAAATGAA 2790
GTAACTTTCAATAAATGCAATATTTATTGGCAGACATTGTTGAAGGAAAAAAGCCAGACAAACAACACTACATAAAATAATGTTTCTATTTAGA 2880
TGAAAGTGGCAAACTAAATCTGTAGTGTAAAAAATTAGATTAGTGAATTCCTGGGCCCAAGTGGCAGGTGGGGAGGATGGCTGCAAGGAAGT 2970
ATGAGGAAACCTTTCTCCAAATAGATGAGAAATTTTCGGTATCTGTGATCTGAGTGGCAAAATGTAAACTTAAAAATATATATAAAATTTATTGA 3060
AAGAAAAATTAAGCCTCAATAAACGTGATTATAAAAAAATAAAAAAAGG 3110

FIG. 5.

90 CGCGCGAGGGCCCCAGCCAGTCAGGGGTGTGGCGCGCCGCCACCGTAAGGCTAGGCGCGAGCTTAGTCTTGGAGCGCGCTCCGTGCG
180 CCGCGGTACAGAGCGCCCTATCAGATTATCTTAACAAGAAAACCAACTGGAAAAAATGAATTCCTTATCTTCGCATTTTTCGGTGG
M K F L I F A F F G G
270 TGTTACCTTTTATCCCTGTGCTCTGGGAAAGCTATATGCAAGATGGCATCTCTAAGAGGACTTTTGAAGAAATAAAGAGAAATAGC
V H L L S L C S G K A I C K N G I S K R T F E E I K E I A
360 CAGCTGTGGAGATGTTGCTAAAGCAATCATCAACCTAGCTGTTTATGGTAAGCCCAAGAACAGATCCTATGAGCGGATTTGGCACTTCTGGT
S C G D V A K A I I N L A V Y G K A Q R S Y E R L A L L V
450 TGATACTGTTGGACCCAGACTGAGTGGCTCCAAGAACCTAGAAAAAGCCATCCAAATATATGTACCAAAACCTGCAGCAAGATGGGCTGGA
D T V G P R L S G S K N L E K A I Q I M Y Q N L Q Q D G L E
540 GAAATTCACTGGAGCCAGTGAGAAATACCCACTGGGAGAGGGAGAGAAATCAGCTGTGATGCTGGAGCCCAAGAAATTCATAGATAGC
K V H L E P V R I P H W E R G E E S A V M L E P R I H K I A
630 CATCTGGGTCTTGGCAGCAGCATTTGGACTCTCTCCAGAGGCAATTAACAGCAGAAAGTTCTGGTGGTGAACCTCTTTCGATGAACTCAGAG
I L G L G S S I G T P P E G I T A E V L V V T S F D E L Q R
720 AAGGCCTCAGAAGCAAGAGGGAAGATTGTTGTTTATTAACCACTTACATCAACTACTCAAGGACGGTGCAATACCGAACGCAGGGGGC
R A S E A R G K I V V Y N Q P Y I Y S R T V Q Y R T Q G A
810 GGTGGAAGCTGCCAAGGTTGGGCTTTGGCATCTCTCATTCGATCCGTGGCTCTCTTCCATCTACAGTCCCTCACACAGGTATTCAGGA
V E A A K V G A L A S L I R S V A S F S I Y S P H T G I Q E
900 ATACCAGGATGGCGTCCCAAGATTCCAACAGCCTGTATTACCGGTGGAAGATGCAGAAATGATGCAAGAAATGGCTTCTCATGGGATCAA
Y Q D G V P K I P T A C I T V E D A E M M S R M A S H G I K
990 AATTGTCAATTACGCTAAAGATGGGGCAAGACCTTACCAGATACTGATTCCTTCAACACTGTAGCAGAGATCACTGGAGCAAAATATCC
I V I Q L K M G A K T Y P D T D S F N T V A E I T G S K Y P
1080 AGAACAGGTTGTACTGTAGTGACATCTGGACAGCTGGGATGTTGGGAGGGTGCCATGATGCGGTGGAGCCTTTATATCATG
E Q V V L V S G H L D S W D V G Q G A M D D G G G A F I S W
1170 GGAAGCACTCTCACTTATTAAGATCTTGGCTGCGTCCAAAGAGGACTCTCGGCTGGTCTCTGACTGCAAGAAACAAGGTGGAGT
E A L S L I K D L G L R P K R T L R L V L W T A E E Q G G V

FIG. 5. (CONTINUED)

1260 TGGTGCCTTCCAGTATTATTCAGTTACACAAGGTAAATATTTCAACTACAGTCTGGTGATGGAGTCTGACGCGAGGAACCTTCTTACCCAC
G A F Q Y Y Q L H K V N I S N Y S L V M E S D A G T F L P T
1350 TGGGCTGCAATTCTACTGGCAGTGAAAGGCCAGGCCCATCATGGAGGAGGTATGAGCCCTGCTGCAGCCCCCTCAATATCACTCAGGTCCT
G L Q F T G S E K A R A I M E E V M S L L Q P L N I T Q V L
1440 GAGCCATGGAGAAGGGACAGACATCAACTTTTGGATCCAAAGCTGGAGTGCCCTGGAGCCAGTCTACTTGATGACTTATACAAGTATTCTTT
S H G E G T D I N F W I Q A G V P G A S L L D D L Y K Y F F
1530 CTTCCATCACTCCACGGAGACACCATGACTGTCTCATGGATCCAAAGCAGATGAATGTTGCTGCTGCTGTTGGGCTGTTGTTCTTATGT
F H H S H G D T M T V M D P K Q M N V A A A V W A V V S Y V
1620 TGTTCAGACATGGAGAATAATGCTGCCTAGGTCCTAGAACACAGTAAGAAGAAAGGTTTTCATGCTTCTGGCCAGGAATCCTGGGTCTGC
V A D M E E M L P R S .
1710 AACTTTGGAAAACTCCTCTTCACATAACAATTTTCATCCAAATTCATCTTCAAGCACAACTCTATTTCATGCTTCTGTTATTATCTTTCT
1800 TGATACTTTCCAAATTCTCTGATTCTAGAAAAGGAATCATTTCTCCCTCCCTCCACACATAGAAATCAACATATGCTAGGATTACAG
1884 TGGGGGCATTTCTTTATATCACCTCTTAAAAACAATTGTTTCCACTTTAAAAAGTAAACACTTAATAAATTTTGGAGATCTCTG

FIG. 6.

NAALAD I	MMNLLHETDSAVATARRPRWLCAGAVULN-GGFFFLGFLFCWPIKSSNEATNTTPKHNK-AFDDSTKNTENKFKFYNFQIEHLAGTQ	88
NAALAD L	-----MCWTKVLELGLGAAALGLGLIILGHFPAIPKANS LAP-----QDLDLEHLETVGGDDAHRIPENREIRREHLAGSPR	75
NAALAD II	-----MAESRSRLYELMCMCAALASFLGFMVGMFIKPLKETTSRYHQSHRMKLSIEVKAENGRSFARSETKLEHLAGTQ	78
NAALAD IV	-----MKFLIPAFPGEVHLLSLCSGKALCKNGSKRTPEEIKKEIASCGDQAKAIINLAVYGAQNRSYERLALLVDIVGRLSESKN	83
NAALAD I	MPQJAKQIQSQMPHPSLDSVELAKDVLSSYPNKHENYISINEDGNENFNTSLFPEPPEYENVSIVPPPSAPSPQSPREGDVA	176
NAALAD L	DEDLVQLLQORWDPSSLSAEAXTVELLSFESQEPVVDIVGPTGGIHSCHRTENVTSEGGPDVUCYAAAPSGTPESELVW	165
NAALAD II	DFLLAKKHQIQQRK--KFLDSAKVHVDVLLSTENETNAIXISLDEHETEFKTEYLEPEPEDEYENVTVIIPENKESACQEMPEEDVW	166
NAALAD IV	LEKAIQINYNQLQ--QDSLEKVTDEEVRIHPHWERGEPESAVMIEPRIHKIALIAGLGSIGTPPE-----	145
NAALAD I	VNYARTDFEIERDKINCSEKVIAPYERVFRGMEVKNQAQLACAKGVILDSDEADYEAPGKKS---YEDENMEGGGVQRENTNLNG	263
NAALAD L	ARG-AEEDPELOTOGKILESTALTPAGGGRGCAVVAHAKHSAVGLVVTGDAINDGLSPDETENSYHPEPSGVVERGSYYEY--	252
NAALAD II	VNYARTDFEIEREKGINCENKVIAPSKKFERGKURKMLAFAIGIILINSDEADYEAPVQOP---YKESMEGTAAQRENTNLNG	253
NAALAD IV	-----ITAEVLLVTSFDETORBASE-APCK-----LVVZINQEXINISRTVOY---RTQSAVEAAKVGALASIDIRSA	208
NAALAD I	AGDPLTEGYEANEZARRGIAZAVSHPSIEVHEIGAYDACKIEKGGSAPEDSHRESIKVPINVSGEFTGNF---STQKKKRNHSTN	350
NAALAD L	FGDPLTEYLPVPSSEPVDTANVSEFEPETQPIGSCDARDLLCMNNTLAF-ATQEAIGCHRLGPGPRPDGDFPADSQMNGYNRL	341
NAALAD II	AEDPLTPGYENKEYTERLDNEEGVSTERIEVHEIGANDAEIILRYIGSLAPEDNKMRGAINVSNISIGEFTGSD---SPRKURRNYNIN	340
NAALAD IV	SFSIYSBHTGICEQD-----SUEKIEFTACTVEDADM SRMA SHGKIKIVIQIMGANTYPTDTS-----	268
NAALAD I	EVTRIENHJITLRSAVEPDRVILGSHRDSWVF-EGTQFQSAVWVHETVSPFTKKKE--LRPKRTILIPASDDEEPFLLGSRNEMAE	437
NAALAD L	ERNSSMULGELIRSAVEPDRVILYNHRDSWVR-SAVLPSSSTAVILSELRLKKE--LRPRRSIVPASGAEFEFLIGSTETTEE	429
NAALAD II	KITRIENHJITLRSAVEPDRVILGSHRDSWVF-SALDITSSVAUQELIARSPFKMSK--LRPRRTIIPASDDEEPFLLGSRNEMAE	427
NAALAD IV	-----EHTQAEHTESKYEFEQVWVAVSHLDSMDVQCEAIGDGGFA---FISWEALSLKDL--LRPKRTILVLTABEQGVCAFTVY--	348

similar to bacterial Zn²⁺ dependent peptidase

FIG. 6. (CONTINUED)

NSRLQERGVAXITACSEHEGNYDRLDCTPLKYSJAHNLTHLKESEDEFEFGKSLYESWTKKSPSEFSGIEHUSKLGSENDEEVEFOR 527
 PFNKLCEPTVAHINVCISPPAIAHNVQGTPEVQSVVP SATHEIRSEGEDLSIYDNMIRYFNRSSEVYGLNESGSGIGAS SOTAPREVHF 519
 NVNLTQERSLAXITSSGSEHEGAYDRLDCTPLKYSJAHNLTHLKESEDEFEFGKSLYESWTKKSPSEFSGIEHUSKLGSENDEEVEFOR 517
 LHKUNISNYSLVHESGAGTFLPTGLQFTG----- 378


LGIAEGRAPVTKWETNKPFGVSLHIEVETTELVERFYDEMFKYHETVQVRGAVEDEANISIVMFFDCRDLAVVVRKADKIYSESMK 617
 LGIISMDIATVYRSKTSARITETHTAFQNTDYDKSLDEGESSHQAVARTASVHLRLSISDFMILKYSSETTSSFLQAAQODLGA 609
 LGIAEGRAPVTKWETNKPFGVSLHIEVETTELVERFYDEMFKYHETVQVRGAVEDEANISIVMFFDCRDLAVVVRKADKIYSESMK 607
 -----EKARATMEEMVSLLCLELNITQLSHGEGTDINMVLQAGVPGA SLDDQLYKYFFFHSHGDTPLVM 443

HPQENKTYSVSLSDSLFSAIKSTTIIISKPSNTQDFDKS--HPIVTFPHDQIMFLERAPTDGLGLDRPVRNWTZAPSSHNNKYAGESP 705
 ---LLECHSLGLGPIVLAHNEREAENAAALGQELSTLOKGSPOPLQVRKMDQIMFLERAPTDGLGLDRPVRNWTZAPSSHNNKYAGESP 693
 HDQPLTDHGVSIEDSLFSLVWNESEASDFHKSLIQVDLN--HPIAHRMHHLQIMFLERAPTDGLGLDRPVRNWTZAPSSHNNKYAGESP 695
 DPKGVNVAAGVAVVSYVGLDVEMLPR9----- 472

BEVYDLFDIESKVDRSKTGEVKKQVYAAFTVCAVIENTSEVA-- 750
 BEVYDLFDIESKVDRSKTGEVKKQVYAAFTVCAVIENTSEVA-- 740
 BEVYDLFDIESKVDRSKTGEVKKQVYAAFTVCAVIENTSEVA-- 740

FIG. 7

Growtree Phylogram of: naaladase_short.distances, Tree Tree_1
June 17, 1998 17:46




	NAALAD I	NAALAD L	NAALAD II	NAALAD IV	APE 3 yeast	P96152	AMPX vibpr	APX strgr
516	RL	QEGVAYINAG	SSI--EGNYTLRWDCTPL	LNYSLVHNLTKED	KSPDEGFEGKSL	YESMTTKS---	PSPEFSGHPRISKLC	
506	KILQERSIAYINSG	SSI--EGNYTLRWDCTPL	LYQLVYKLTKENP	SPDDGFESKSL	YESMLEKD---	PSPENKNLPRINKLC		
508	KL-QEFTVAYINVG	ISV-FANATLRQGP	PPVQSVVFSAPKE	IRSPGPGD---	LSIYDNTIRYFNRRSPV	YGLVPSLGSLS		
404	NIS--NYSLVHES	AGT-FLPTGLQFTGSE	KARA----	INEEVM----	SLQLPLNITQ----	VLSHG		
435	ENSKIR--VFINDYD	HMA-SPNYEYETD	ANNKENP--	KGEEDK----	NLYVDYTKAH----	HLNYTLVPFDG		
327	QGK--KQSVLQLQ	NTNYRGS AED	INFIIDYTDS----	NLQQLT----	TLIDEVLPEL----	TYG----	YDRCE	
330	EKG--NVVSALQLQ	NTNYKGS AQD	WFIIDYTDS----	NFQQLT----	QLHDEYLP SL----	TYG----	FDTCE	
210	AD-RSHLAGYLNFTD	N-IGSPNPGYFY	YDDDPVIEK--	TFKNYFAG----	LNVPTEIETE----	GDGRSDHAPFKN		

FIG. 8. (CONTINUED)


NAALAD I	SGNDFEVFFQRL	IASGRARYT	ANWETNKF	SGYPL	YHSVYET	VELWEK	----	FYDPM	KYH	-L	TV	QVRGG	----	582																													
NAALAD I	SGSDFEAYQRL	IASGRARYT	ENKKT	KYSSYP	VYH	IYET	FELWEK	----	FYDPT	KKQ	-LS	V	QLRGA	----	572																												
NAALAD II	AGSDYAPFVHFL	ISSHD	IAYTYDR	SKTSARI	YPT	YH	IAFD	TF	DY	DK	----	FLDPG	SSH	-Q	AV	RTAGS	----	574																									
NAALAD IV	EGTDIN-F	IQAGVPG	ASLLDD	LKYFF	----	FHS	HGDT	INTV	HD	PKQ	MV	AAAV	LAV	VS	YV	AD	NHEE	LPRS	----	472																							
APC 3 yeast	RSDYVGF	INNGIP	AGGIAT	GAEFNN	VNNGK	VLDR	CYH	QLCDD	VSN	LS	UDAF	ITNT	KL	I	AH	SV	AT	Y	DS	FEG	FPK	RETQKH	515																				
P96152	YACSDHAS	GHK	AFSA	AMPFES	FKDYN	----	PK	HT	TSQD	TL	ANS	DPT	----	GN	H	AV	T	TKL	G	L	A	Y	VIEMAN	391																			
AMPX vibpr	YACSDHAS	GHNA	CYP	AAMPFES	KFNDYN	----	PR	HT	TQD	TL	ANS	DPT	----	G	S	H	A	K	K	T	Q	L	A	Y	VIEMAN	394																	
APX strgr	VGVPVGG	LE	TG	AFYTK	SA	AQAQ	WGG	TAG	QAF	DR	CYH	ES	SCD	SL	SN	END	T	A	L	D	R	N	S	D	A	A	A	H	A	I	U	T	L	S	S	G	T	G	E	P	T	----	284

FIG. 9.

A



B



C




FIG. 10.





FIG. 11.





FIG. 12.

A



B






FIG. 13.


A




B



C



D



E




FIG. 14.









FIG. 15.



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: DOTS on original document

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.